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ABSTRACT
Epithelial ovarian cancer (EOC) encompasses a heterogenous group of malignancies 
with a poor overall survival rate.  The two root problems behind the poor survival 
of patients are the lack of precise enough biomarkers to enable screening and early 
detection of the disease and the development of a chemotherapy resistant, fatal 
disease. 
Cancer antigen 125 (CA125) is currently the only biomarker validated and widely 
adopted in the diagnosis, treatment monitoring and follow-up of EOC. However, 
CA125 is not the ideal biomarker, as it is non-specific for EOC and does not relia-
bly express changes in tumor load. In the current study, the feasibility of four novel 
biomarkers were investigated: CA125-STn and -MGL, human epididymis protein 4 
(HE4) and circulating tumor DNA (ctDNA).
This prospective study included 253 women with histologically confirmed EOC, 
317 women with benign gynecological diseases and 36 healthy controls. Both CA125-
STn and -MGL differentiated EOC from benign diseases with improved specificity 
compared to conventional CA125. In the longitudinal analyses, HE4, CA125-STn 
and -MGL, contrarily to CA125, showed good correlation with tumor burden. In 
addition, HE4 at the time of progression predicted the survival of patients. The longi-
tudinal mutation tracking of plasma ctDNA revealed dynamic, actionable mutations 
during EOC treatment and follow-up.
CA125-STn and -MGL are EOC-specific biomarkers that showed, similar to HE4, 
good prognostic potential. The CA125 glycoform assays utilize a robust and afforda-
ble measurement technique, which makes them feasible biomarkers also in the clini-
cal setting. Based on the current study, HE4 is an indicator of disease aggressiveness 
and might be a potential tool in the selection of targeted second line treatments. 
Similarly, the ctDNA analyses revealed actionable mutations enabling the individual 
treatment of selected HGSC patients. Overall, these novel biomarkers represent state 
of the art approaches in the diagnosis, treatment monitoring and follow-up of EOC.
KEYWORDS: Epithelial ovarian cancer, cancer antigen 125, glycoforms, human 
epididymis protein 4, ctDNA
5
TURUN YLIOPISTO, 
Lääketieteellinen tiedekunta
Synnytys- ja Naistentautioppi
Gynekologinen onkologia
LIINA SALMINEN: Uudet serologiset ja geneettiset merkkiaineet 
 epiteliaalisessa munasarjasyövässä.
Väitöskirja
Turun kliininen tohtoriohjelma
Lokakuu 2020
TIIVISTELMÄ
Epiteliaaliset munasarjasyövät ovat sekalainen ryhmä pahanlaatuisia kasvainsairauk-
sia, joita yhdistää huono selviytymisennuste. Kaksi keskeistä syytä potilaiden huo-
noon selviytymiseen ovat puute aikaisen diagnostiikan ja seulonnan mahdollistavista 
merkkiaineista ja hoitoresistentin, loppuvaiheen sairauden kehittyminen.
Cancer antigen 125 (CA125) on tällä hetkellä ainoa validoitu ja laajalti käytetty 
merkkiaine munasarjasyövän diagnostiikassa, hoitovasteen arvioinnissa ja seuran-
nassa. CA125 ei kuitenkaan ole kyllin hyvä merkkiaine, koska se ei ole spesifinen 
munasarjasyövälle eikä se luotettavasti osoita muutoksia kasvaintaakassa. Tässä tut-
kimuksessa selvitettiin neljän uuden kasvainmerkkianeen käytettävyyttä munasarja-
syövässä: CA125-STn ja -MGL, human epididymis protein 4 (HE4) ja circulating 
tumor DNA (ctDNA).
Tutkimuskohortti koostui 253:sta munasarjasyöpää sairastavasta naisesta ja 
317:sta naisesta, joilla oli hyvänlaatuinen gynekologinen sairaus. Verrokkiryhmään 
kuului myös terveitä naisia. Sekä CA125-STn, että -MGL erottivat munasarjasyövän 
hyvänlaatuisista sairauksista paremmalla tarkkuudella kuin CA125. Pitkittäisanalyy-
seissä HE4, CA125-STn ja MGL osoittivat hyvää yhteyttä tautitaakkaan, toisin kuin 
CA125. Lisäksi HE4-taso taudin uusimishetkellä ennusti potilaiden selviytymisaikaa. 
Pitkittäinen ctDNA-mutaatioprofiilin määrittäminen paljasti hoidon ja seurannan 
aikaisia, dynaamisia mutaatiota. 
CA125-STn ja -MGL ovat munasarjasyöpäspesifejä kasvainmerkkiaineita, jotka 
osoittivat, samoin kuin HE4, ennusteellista hyötyä munasarjasyövän seurannassa. 
CA125-STn ja -MGL -paneelit hyödyntävät vakaata ja edullista analysointi tekniikkaa, 
minkä ansiosta ne ovat myös kliiniseltä käytettävyydeltään hyviä. Tämän tutkimuksen 
perusteella HE4 vaikuttaisi kertovan potilaan munasarjasyövän aggressiivisuudesta 
ja HE4-määritys saattaa siksi olla mielekäs työkalu yksilöllisten, toisen linjan hoito-
jen valitsemisessa. Samankaltaisesti, ctDNA-analyysi paljasti kohteita täsmähoidoille 
valituissa munasarjasyöpäpotilaissa.
AVAINSANAT: Epiteliaalinen munasarjasyöpä, CA125, glykoformit, ctDNA, HE4
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CNA Copy number alteration
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PFS Progression free survival
PI3KCA PIK3 catalytic subunit alpha
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RECIST Response Evaluation Criteria in Solid Tumors
RMI Risk Malignancy Index
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ROMA Risk of Ovarian Malignancy Algorithm
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1 Introduction
Approximately 295 000 women worldwide, of which 550 women in Finland, received 
the diagnosis of epithelial ovarian cancer in 2018 (Finnish Cancer Registry, 2018; 
Bray et al., 2018). EOC is an aggressive malignancy with an unfavorable outcome, as 
the 5-year survival of patients falters at 44%  (Finnish Cancer Registry, 2018). Early 
diagnosis has proven to be an uphill struggle, and the meager survival rate is mainly 
due to extensive tumor load at the time of diagnosis. At present, ovarian cancer, 
alongside cervical cancer, has the highest mortality among patients with gynecologi-
cal malignancies in developed countries (Bray et al., 2018). 
The mainstay of EOC treatment is aggressive cytoreductive surgery with subse-
quent platinum-based chemotherapy (Benedet et al., 2000). Even though primary, 
therapy-naïve EOC responds initially well to treatment, most patients eventually 
develop a treatment-resistant refractory disease, which is another major cause of 
lethality. This thesis focuses on novel, putative biomarkers in the early diagnostics, 
treatment monitoring and follow-up of EOC.
 Currently, the cancer antigen 125 (CA125) is the gold standard of biomarkers in 
the diagnosis, treatment monitoring and follow-up of patients with EOC. However, 
CA125 has several limitations: 1) the serum level of CA125 is elevated in only 50% 
of early stage EOCs, 2) the correlation of CA125 to tumor volume is questionable, as 
small amounts of residual disease are present in up to 50% of patients regardless of 
CA125 normalization and 3) serum CA125 is elevated in various benign diseases and 
non-EOC malignancies (Bast et al., 2005). Thus, it has become evident that better 
diagnostic and prognostic EOC biomarkers are needed. Human epididymis protein 4 
(HE4) was recently approved as an auxiliary biomarker to CA125 in the diagnosis of 
EOC. However, HE4 has its own limitations and it is still under debate whether HE4 
improves the detection of early stage EOC (Jacob et al., 2011; Kristjansdottir et al., 
2013). In addition, the routine measurement of HE4 in EOC treatment monitoring 
and follow-up is currently not recommended as clinical data on the subject is insuf-
ficient (Colombo et al., 2019). 
In this study, we prospectively evaluated the diagnostic and prognostic potential 
of two cancer-specific CA125 glycoform assays (CA125-MGL and -STn) in patients 
with EOC. These two assays have shown good diagnostic potential in preclinical 
studies, which made them putative candidates for exploratory clinical trials (Gidwani 
13
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et al., 2016, 2019). Longitudinal analyses with the glycoform and HE4 assays were 
done and the correlation of the biomarkers to tumor burden and their ability to 
detect recurrent disease was assessed. 
The analysis of circulating tumor DNA (ctDNA) represents a non-invasive, state 
of art approach in EOC diagnostics, prognosis assessment and real-time evaluation 
of treatment resistance (Barlebo Ahlborn and Østrup, 2019; Zhao, Cardenas and 
Matei, 2019). CtDNA analysis could be especially valuable in situations when con-
ventional tissue biopsies might not represent the tumor in a comprehensive manner, 
e.g. heavily pretreated patients or patients with rapidly growing, necrotic tumors. 
We examined the feasibility of ctDNA mutation tracking in a prospective study and 
carefully assessed the utility of plasma ctDNA in the real-time detection of actionable 
mutations during EOC treatment.
14
2 Review of the Literature
2.1 Epithelial Ovarian Cancer (EOC)
2.1.1 History of EOC Research: From the “Silent Killer”  
to the “Whispering Disease”
The natural history of ovarian cancer was described for the first time in 1873 by 
Thomas Spencer Wells, an English physician (Wells, 1873). He presented that ovarian 
malignancies arise from ovarian surface epithelium, and the theory was further inves-
tigated by Wilfred Shaw in 1923;  ‘The general form of a malignant papillomatous 
serous cyst implies a development from a papillomatous serous cyst of the ovary... I 
have been unable to demonstrate histological evidence of any such transition’ (Shaw, 
1932). Although Dr. Shaw was not able to prove the theory of malignant transforma-
tion, it remained the leading theory of ovarian cancer pathogenesis for decades and 
has since been proven correct in some subtypes of ovarian cancers (Prat, D’Angelo 
and Espinosa, 2018). 
The metaphor of ovarian cancer as the “silent killer” set root promptly due to the 
apparent lack of symptoms in early stages of disease progression. In the mid twen-
tieth century, ovarian cancer was a recognized disease, but no hope for cure was 
offered. Researchers mainly focused on the development of palliative methods, such 
as the alkylating agent hemisulfide mustard, to ease the obstructive symptoms caused 
by the accumulation of ascites fluid (Seligman et al., 1952). It was decades later that 
the disease caught the attention of the scientific community at a larger scale, as its 
incidence appeared to be on the rise: in the 1960s 1 in 100 women was estimated 
to develop ovarian cancer, while the risk of developing the disease was reported to 
have risen to 1 in 70 women by the 1980s (Jasen, 2009). Consequently, studies on 
the long-neglected epidemiology of ovarian cancer were conducted, and emerging 
evidence of women with increased risk for ovarian cancer was laid out, specifically, 
low parity and hereditary factors (Jasen, 2009). Simultaneously, the initial study on 
a platinum-based agent, cisplatin, in the treatment of ovarian cancer was conducted 
with promising results: 9/34 patients responded to therapy (Wiltshaw and Kroner, 
15
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1976), and the results introduced the modern era of ovarian cancer chemotherapy 
(Steven Piver, 2006). Advancement in the diagnostic field was achieved, as the 
development of a murine monoclonal antibody in 1979 lead to the development 
of the cancer antigen 125 (CA125) biomarker assay in 1983 (Bast et al., 1983). The 
subsequent improvement in diagnostics and increasing opportunities for supportive 
care enabled a more radical treatment approach, which resulted in improved survival 
outcomes (Barber, 1986). Recently, the Human Genome Project and further genomic 
profiling has shifted the scientific thought of  ovarian cancer research beyond an “one 
size fits all” solution (Previs et al., 2017). Generally speaking, the scientific advances 
of the last century have shifted the image of ovarian cancer from an incurable killer 
to a manageable disease.
2.1.2 Epidemiology and Etiology
Ovarian cancer is the seventh most common cancer in women worldwide with 
approximately 295 000 new cases every year (Bray et al., 2018). In Finland, ovarian 
cancer is the eight most common cancer in women with circa 550 new cases annu-
ally (Finnish Cancer Registry, 2018). The incidence of ovarian cancer is declining 
in developed countries but rising in developing countries, mostly due to increasing 
life-expectancy (Ferlay et al., 2013). Annually, circa 185 000 women die of ovarian 
cancer and it is the most lethal gynecological cancer, alongside cervical cancer, in 
developed countries (age-standardized mortality: 3.8 per 100 000 person-years in 
high/very-high human development index regions and 4.8 per 100 000 person-years 
in Finland) (Finnish Cancer Registry, 2018; Bray et al., 2018). Despite the advances 
in cancer treatment, the 5-year survival rate of ovarian cancer patients falters at 44% 
as most patients are diagnosed with advanced disease (International Federation of 
Gynecology and Obstetrics, FIGO, stage III–IV) (Finnish Cancer Registry, 2018). 
Ovarian cancer is rare in patients < 40 years of age and the majority of ovarian malig-
nancies in young patients are germ cell tumors (Webb et al., 2017). Contrarily, EOC 
accounts for most of the ovarian cancers in older age groups (Webb et al., 2017). 
EOC is a group of heterogenous diseases; consequently, the risk factors vary 
between the histological subtypes. However, several common risk factors have been 
determined with various robustness, ranging from established to unlikely risk fac-
tors (Table 1). The majority of EOCs are sporadic, but a hereditary predisposition to 
EOC is well established (Malander et al., 2006; Wentzensen, Poole and Trabert, 2016; 
Andrews and Mutch, 2017; Webb et al., 2017). Specifically, breast cancer genes 1 and 
2 (BRCA1 and BRCA2) mutations causing the breast and ovarian cancer syndrome 
(14% of EOCs and 17% of HGSC) and in a lesser extent mutations in the mismatch 
repair genes (MMR-genes) resulting in Lynch syndrome (2% of EOCs) (Malander 
et al., 2006; Andrews and Mutch, 2017). Women with Lynch syndrome generally 
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develop EOC at a younger age than women with sporadic EOC, with a predisposition 
to endometroid and clear cell carcinomas (Helder-Woolderink et al., 2016). Further, 
women with a history of EOC in the family have an elevated risk of developing EOC 
regardless of their genetic status (Andrews and Mutch, 2017). Other well-established 
risk factors are endometriosis, smoking, hormone replacement therapy (HRT) and 
obesity (Heidemann et al., 2014; Webb et al., 2017). Smoking has been specifically 
associated with and increased risk of developing mucinous carcinoma (relative risk 
1.78; 95% CI 1.52–2.07) (Santucci et al., 2019). In contrast, the continuous use of 
estrogen only HRT for over 5 years has shown to increase the risk of serous carcinoma, 
but decreased the risk of mucinous carcinoma (Koskela-Niska et al., 2013). The use 
of oral contraceptives, pregnancy and tubal ligation have been shown to decrease 
the risk of EOC (Webb et al., 2017). Women with a history of oral contraceptive 
use for over 10 years had a 36% to 49% reduction in the risk of developing serous, 
endometroid or clear cell carcinomas in a study by Wentzensen et al (Wentzensen, 
Poole and Trabert, 2016). The strongest protective association of pregnancy to EOC 
was detected in clear cell carcinomas (relative risk 0.35; 95% CI 0.27–0.47), while the 
risk of developing serous carcinoma was least reduced by pregnancy (relative risk 
0.81; 95% CI 0.73–0.90) (Wentzensen, Poole and Trabert, 2016). 
Table 1. Risk and protective factors of EOC. Modified from (Webb et al., 2017).
Association Increased risk Decreased risk
Established Family history of EOC Pregnancy > 6 months
Endometriosis Oral contraceptive use
Smoking Tubal ligation
Estrogen only HRT
Greater height
Obesity
Probable Older age at menopause Breastfeeding
Possible Younger age at menarche Older age at last birth
Combination HRT Aspirin
Pelvic inflammatory disease Vitamin D
Diabetes mellitus
Talc (genital use)
Unlikely or 
insufficient 
evidence
Infertility treatment, hysterectomy without oophorectomy, PCOS, fibroids 
or ovarian cysts, alcohol intake, diet, physical activity
HRT: hormone replacement therapy, PCOS: polycystic ovarian syndrome
17
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2.1.3 Pathogenesis
2.1.3.1 Histological Classification
EOC is divided into four distinct cell types based on the normal epithelia in the 
female reproductive organs: endometroid, clear cell, mucinous and serous (Koshi-
yama, Matsumura and Konishi, 2014, 2017; Prat, D’Angelo and Espinosa, 2018). It 
is evident that EOCs are tumors with different clinicopathological and genetic fea-
tures. Thus, a dualistic model has been established in the histological classification 
of EOC subtypes into type 1 and type 2 tumors (Kurman and Shih, 2016).  Type 
1 tumors generally develop from precursory benign ovarian lesions in an adeno-
ma-carcinoma continuum, they are often confined to the ovary and pelvis and are 
genetically stabile (Kurman and Shih, 2016). Type 1 tumors include endometroid, 
clear cell, mucinous and low grade serous carcinomas (Kurman and Shih, 2016). It 
is recognized that endometroid and clear cell carcinomas generally develop from 
atypical endometriosis, while low grade serous carcinoma evolve from serous bor-
derline tumors in a stepwise fashion (Prat, D’Angelo and Espinosa, 2018). The origin 
of mucinous carcinoma is incompletely understood, but it is suspected that it devel-
ops from benign cystadenomas or mucinous borderline tumors (Prat, D’Angelo and 
Espinosa, 2018). Type 2 tumors are genetically instable and metastasize aggressively 
(Kurman and Shih, 2016). There is increasing evidence that type 2 tumors origin 
from malignant precursory lesions in the distal fallopian tube and/or the ovary i.e. 
serous tubal intraepithelial carcinoma (STIC) (Piek, Kenemans and Verheijen, 2004). 
Interestingly, a recent study on the origin of HGSC reported that the ancestral clone 
of the subsequently observed HGSC was identifiable in the STIC lesion of the patient, 
further illuminating the origin of HGSC (Labidi-Galy et al., 2017). HGSC is classified 
as a type 2 tumor (Kurman and Shih, 2016). 
2.1.3.2 Molecular Features
In addition to the distinct histological features of the EOC subtypes, the divergent 
molecular genomics of the diseases have been illuminated in recent years. Molecular 
tools, such as deep sequencing, ribonucleic acid (RNA) sequencing, epigenomics and 
proteomics have made it apparent that the molecular heterogeneity of EOC explains, 
to certain extent, the poor survival outcomes of patients (Kossaï et al., 2018). The 
main molecular features of the histological subtypes are presented in Table 2.
The large scale genomic analysis of HGSC shows mutations in tumor protein 
53(TP53) in 96% and BRCA1/2 mutations in 22% of the tumor samples (The Cancer 
Genome Atlas Research Network, 2011). In addition, six more significantly mutated 
genes have been described in 2–6% of HGSC tissue samples (CSMD3, NF1, CDK12, 
18
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FAT3, GABRA6, RB1) (The Cancer Genome Atlas Research Network, 2011). Genetic 
and epigenetic alterations in homologous recombination (HR) pathways are present 
in up to 50% of HGSCs (Konstantinopoulos et al., 2015). In addition, a high number 
of copy number alterations (CNAs) has been linked to HGSC, which might, to some 
extent, be due to the high prevalence of alterations in the HR- pathways (The Cancer 
Genome Atlas Research Network, 2011; Konstantinopoulos et al., 2015). HGSC 
immunohistochemistry is positive for CK7, PAX8 and WT, and negative for CK20 
(Kossaï et al., 2018)(Table 2).
A low grade serous carcinoma (LGSC) is morphologically similar to HGSC, how-
ever, it is characterized by genomic stability and no TP53 mutations (Kossaï et al., 
2018). The mutation profile of LGSC differs from that of HGSC, and LGSC tumors 
generally present mutations in the KRAS or BRAF (Ramalingam, 2016). Endometri-
oid carcinoma generally show abnormal expression of CTNNB1, PI3KCA, PPP2R1A, 
PTEN and ARID1A (Kossaï et al., 2018). Interestingly, these mutations have also 
been found in endometriotic cysts indicating a stepwise malignant transformation 
(Kossaï et al., 2018). Similar to LGSC, clear cell carcinoma rarely express mutations in 
TP53 or BRCA 1/2 (Lheureux et al., 2019). Frequent molecular aberrancies presented 
in clear cell carcinoma include mutated SWI/SNF (SWItch/Sucrose Non-Fermenta-
ble) chromatin-remodeling complex genes (specifically  ARID1A) 40–60%,  PIK3CA 
33% and PTEN 37% (Kossaï et al., 2018; Lheureux, Braunstein and Oza, 2019). Muci-
nous carcinomas are typically heterogeneous tumors and harbor areas of mucinous, 
benign, borderline and adenocarcinoma origin (Kossaï et al., 2018). The molecular 
pattern of mucinous carcinoma consists of mutations in KRAS (50–75%) and HER2 
(20%), which are generally mutually exclusive (Kossaï et al., 2018; Lheureux, Braun-
stein and Oza, 2019). Mucinous carcinomas with neither KRAS or HER2 mutations 
have an increased inclination to disease recurrence and subsequent mortality than 
tumors with either mutation (Prat, D’Angelo and Espinosa, 2018). The immunophe-
notypes of the EOC subtypes are presented in Table 2.
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Table 2. Histopathological and molecular features of the 5 major subtypes of EOC.  
Modified from (Kossaï et al., 2018).
HGSC LGSC EC CCC MC
Frequency 70% <5% 10% 5–10% 2–3%
Immunophenotype CK7+, 
CK20–, 
PAX8+, 
WT1+
CK7+, 
WT1+, 
ER+
CK7+, PAX8+, 
CK20–, WT1–
napsin A+, 
WT1–, p53–, 
ER–
CK7+, 
CK20–, ER–, 
PR–, WT1–
Precursor lesion STIC Low 
grade 
malignant 
potential 
lesions
Endometriosis Endometriosis Borderline 
mucinous 
lesions
Molecular 
abnormalities
TP53, 
BRCA 
1/2
KRAS, 
BRAF
ARID1A, 
PTEN
ARID1A, 
PIC3CA, 
PTEN
KRAS, HER2
LGSC: low grade serous carcinoma, EC: endometroid carcinoma, CCC: clear cell carcinoma, 
MC: mucinous carcinoma, STIC: serous tubal intraepithelial carcinoma
2.1.3.3 Spread Patterns
The spread pattern of EOC is unique in comparison to other epithelial cancers, 
as extra-abdominal spread is rarer and represents late stage disease (Peters et al., 
2015). The two main types of EOC spread are tumor cell shedding and metastasis 
intra-abdominally, and dissemination to the retroperitoneal lymphatic drainage 
areas. Hematogenous spread has generally been considered rare, but recent studies 
have suggested that it might be a more common modality of spread than previously 
thought (Sunila et al., 2015; Coffman et al., 2016). 
Preceding metastatic shedding, EOC tumor cells undergo a transition from epi-
thelial-to-mesenchymal and then detach from the primary tumor (Lengyel, 2010). 
Tumor cells disseminate as single cells or clusters with the physiological flow of the 
peritoneal fluid. Consequently, the typical intra-abdominal metastatic sites of EOC 
are the right subdiaphragmatic peritoneum, paracolic gutters and the omentum (van 
Baal et al., 2017).  The dissemination of EOC cells results in the development of 
peritoneal carcinomatosis; however, the invasion of the peritoneal stroma remains 
largely superficial (van Baal et al., 2017). In incidental cases, the tumor cells infiltrate 
the walls of the intestine and bladder. 
The lymphatic drainage routes from the ovaries run through the infundibu-
lopelvic and ovarian ligaments, and to some extent through the round ligament of 
the uterus (Kleppe et al., 2015). Lymphatic metastases are present in up to 85% of 
patients with advanced EOC (Aletti, 2018) and the typical metastatic sites are the 
20
Liina Salminen
para-aortic and paracaval regions, the obturator fossa and surrounding the inter-
nal iliac arteries (Kleppe et al., 2015). In contrast, supradiaphragmatic lymph node 
metastases originate mainly from intra-abdominal tumor growth (anterior route of 
lymphatic drainage) and are considered distant metastases (Mutch and Prat, 2014). 
Other sites of extra-abdominal metastases include pleural carcinosis and subsequent 
pleural effusion, inguinal lymph node, and intraparenchymal liver metastases.
2.1.4 Clinical Presentation and Primary Diagnostics
The conventional symptoms associated with EOC are pelvic pain and/or bloat-
ing, abdominal distension, a palpable abdominal mass and loss of appetite. Other 
symptoms include changes in bowel movement, constipation, urinary problems 
and vaginal bleeding (Ebell, Culp and Radke, 2016). In some cases, a deep venous 
thromboembolism (DVT) is the first sign of EOC. In fact, EOC is a malignancy with 
one of the highest rates of concomitant DVTs (Blom et al., 2006).  On the whole, the 
symptoms suggestive of EOC are generally diffuse and become more persistent as 
the disease advances. Consequently, EOC has been referred to as “the silent killer” as 
early detection of the disease based on symptoms has remained unlikely.
A physical examination is done at the primary health care center and/or at the 
gynecologic outpatient clinic when a suspicion of EOC arises. A gynecological exam-
ination, including a speculum examination and a bimanual palpation, gives essential 
information of the mobility of the uterus and the size of the ovaries. Palpable ovaries 
in a postmenopausal woman is always atypical and further diagnostic investigations 
are needed. Moreover, a digital rectal examination is considered and all areas with 
superficial lymph nodes should be carefully assessed.  A transvaginal sonography 
(TVS) is part of the basic diagnostic inspection of these patients. Suspicious TVS 
findings include ovarian masses >6cm and complex, irregular or bilateral smaller 
masses (Eskander, Berman and Keder, 2016). The serum levels of cancer antigen 125 
(CA125) and occasionally human epididymis protein 4 (HE4) are determined. How-
ever, the sensitivity of the CA125 and HE4 assays in the detection of early stage EOC 
is suboptimal (55% for both assays, Wang et al., 2014) and multimarker panels have 
been developed to mend the problem: The Risk of Ovarian Malignancy Algorithm 
(ROMA), Risk Malignancy Index (RMI) and Copenhagen Index (CPH-I) (Jacobs et 
al., 1990; Van Gorp et al., 2011; Karlsen et al., 2015). These panels build on the bio-
markers CA125 and HE4, TVS and/or the patients age/menopausal status. Although, 
the diagnostic performance of these panels have shown impressive results (AUCs 
0.89, 0.86 and 0.88 for ROMA, RMI and CPH-I, respectively) in discriminating early 
stage EOC from benign diseases, there has been debate on whether these results can 
be translated into clinical utility (Van Gorp et al., 2011; Karlsen et al., 2015). In all 
patients, a CT scan of the abdomen and a chest x-ray or a whole-body CT are used to 
21
Review of the Literature
detect extrapelvic disease preoperatively (Hennessy, Coleman and Markman, 2009). 
Additionally, the CT scan is a feasible method of evaluating the up-front cytoreduct-
ibility of the disease. In patients with ascites and/or pleural effusion, the cytology can 
be assessed if therapeutic paracentesis is needed. However, waiting for the cytology 
results is not necessary as the definitive diagnosis is attained from biopsies taken 
during surgery or a needle biopsy of the carcinosis.
2.1.5 Screening
The evident difficulties in the early detection of ovarian cancer and the notion that the 
mortality of the disease could be decreased with an early intervention has resulted in 
studies on ovarian cancer screening. Two randomized controlled trials on the effect 
of screening on ovarian cancer mortality have been conducted and unfortunately, 
the screening with CA125, TVS or the Risk of Ovarian Cancer Algorithm did not 
significantly decrease disease-specific mortality (Buys, 2011; Jacobs et al., 2016). 
However, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) did 
offer some encouraging results, as the results of the study indicated that a significant 
reduction in mortality might be seen during a longer follow-up period (Jacobs et al., 
2016). The hypothesis is based on the finding that the mortality hazard ratio in the 
screening group seemed to subside, meanwhile an increasing trend was detected in 
the no screening group (Jacobs et al., 2016). Currently, the efficacy of ovarian cancer 
screening is not proven, and the screening methods need to be refined with more 
specific biomarkers/imaging studies for it to be feasible. 
2.1.6 Staging
EOC is staged based on a surgical staging system established by The International 
Federation of Gynecology and Obstetrics (FIGO) Committee on Gynecologic 
Oncology (Table 3). The staging procedure includes extrafascial hysterectomy, 
bilateral salpingo-oophorectomy, radical omentectomy, appendectomy and pelvic 
and para-aortic lymphadenectomy (Benedet et al., 2000). Biopsies are taken con-
sistently from all suspicious cites (mesentery of the small and large intestines, liver 
and diaphragm) and cytologic data is collected from peritoneal washings (Heintz 
et al., 2006). Although the staging system is surgical, the disease stage is confirmed 
histologically by a pathologist, and changed if necessary. As previously mentioned, 
a clinical examination is done prior to surgery and it is essential in confirming the 
disease stage. The FIGO classification corresponds well with the generally used TNM 
classification of solid tumors. 
Stage I and II tumors are confined to the pelvis and are considered early stage 
(Prat, 2014) (Table 3). Although only 31% of all EOCs are diagnosed at an early stage, 
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the majority (58%–64%) of endometroid, mucinous and clear cell carcinomas are 
diagnosed at stage I (Torre et al., 2018). Consequently, these tumors have decent 5 
year survival rates of 82%, 71% and 66% for endometroid, mucinous and clear cell 
carcinoma, respectively (Torre et al., 2018). Stage III tumors have spread intra-ab-
dominally outside the pelvis and/or to the retroperitoneal lymph nodes and stage IV 
tumors present with distant metastases (pleural effusion, extra-abdominal tumors 
and growth to the liver parenchyma or other visceral organs) (Prat, 2014) (Table 3). 
Most of EOCs (60%) are diagnosed at stage III or IV, and patients have meager 5 year 
survival rates of 41% (stage III) and 20% (stage IV) (Torre et al., 2018). Importantly, 
80% of HGSCs are diagnosed at a late stage and this illuminates the aggressive nature 
of the most common subtype of EOC as the 5 year survival rate of patients diagnosed 
with HGSC is 43% (Torre et al., 2018). 
2.1.7 Prognostic Factors
There are several prognostic factors associated with poor survival outcomes in 
patients with advanced EOC: old age, poor physical performance status, tumor his-
tology (mucinous and clear cell) and suboptimal cytoreduction (Winter et al., 2007). 
Similarly, old age, high disease stage and grade, and positive peritoneal washings 
have been identified to correlate with worse prognosis in early stage EOC (Chan et 
al., 2008). In addition, emotional disorders worsen the prognosis of elderly patients 
(Tinquaut et al., 2016). Interestingly, body mass index (BMI) does not seem to play a 
role in the survival of EOC patients (Kotsopoulos et al., 2012). 
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Table 3. FIGO 2014 classification system and the corresponding TNM.  
Modified from (Prat, 2014).
Stage I. Tumor confined to the ovaries and/or fallopian tube(s)
IA (T1a, N0-M0) Tumor limited to one ovary (capsule intact) or fallopian 
tube; no tumor on ovarian or fallopian tube surface; no 
malignant cells in the ascites or peritoneal washings
IB (T1b, N0-M0) Tumor limited to both ovaries (capsules intact) or fallopian 
tubes; no tumor on ovarian or fallopian tube surface; no 
malignant cells in the ascites or peritoneal washings
IC1 (T1c1, N0-M0) Surgical spill
IC2 (T1c2, N0-M0) Capsule ruptured before surgery or tumor on ovarian or 
fallopian tube surface
IC3 (T1c3, N0-M0) Malignant cells in the ascites or peritoneal washings
Stage II. Tumor confined below the pelvic rim or primary peritoneal cancer
IIA (T2a, N0-M0) Extension and/or implants on uterus and/or fallopian tubes 
and/or ovaries
IIB (T2b, N0-M0) Extension to other pelvic intraperitoneal tissues
Stage III. Tumor spread to the peritoneum outside the pelvis and/or  
metastasis to the retroperitoneal lymph nodes
IIIA1(T3a2, N0/N1-M0) Positive retroperitoneal lymph nodes only (cytologically  
or histologically proven)
IIIA1 (i) Metastasis up to 10 mm in greatest dimension
IIIA1 (ii) Metastasis more than 10 mm in greatest dimension
IIIA2 Microscopic extra-pelvic peritoneal involvement with  
or without positive retroperitoneal lymph nodes
IIIB (T3b, N0/N1-M0) Macroscopic peritoneal metastasis beyond the pelvis up  
to 2 cm in greatest dimension, with or without metastasis  
to the retroperitoneal lymph nodes
IIIC (T3c, N0/N1-M0) Macroscopic peritoneal metastasis beyond the pelvis more 
than 2 cm in greatest dimension, with or without metastasis 
to the retroperitoneal lymph nodes 
Stage IV. Distant metastasis excluding peritoneal metastases
IVA (any T, any N, M1) Pleural effusion with positive cytology
IVB (any T, any N, M1) Parenchymal metastases and metastases  
to extra-abdominal organs
2.1.8 Treatment of Primary EOC
Cytoreductive surgery followed by intravenous chemotherapy is the foundation of 
primary EOC treatment. There are two validated strategies for primary treatment: 
(1) primary debulking surgery (PDS) followed by adjuvant chemotherapy and (2) 
neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) with 
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subsequent adjuvant chemotherapy (patients with advanced, stage III–IV disease) 
(Kehoe et al., 2015; Yang et al., 2017) (Figure 1). For optimal treatment results, 
cytoreductive surgery should be done by a gynecologic oncologist and a comprehen-
sive multidisciplinary approach is recommended (Giede et al., 2005; Fagotti et al., 
2016). In addition to the oncological treatments, psycho-oncological support should 
routinely be provided and the identification of  psychosocial distress, sexual dysfunc-
tion and psychiatric comorbidity is important (Colombo et al., 2019).
Figure 1. Treatment flowchart of EOC patients in the Turku University Hospital.
2.1.8.1 Laparoscopy
Minimally invasive surgery (MIS) has been implemented in the treatment of primary 
EOC and it has been proven feasible in the cytoreductive surgery of apparent early 
stage EOC and in the staging of advanced disease (Gallotta et al., 2014; Fagotti et al., 
2016). Still, open surgery is considered the standard approach even in apparent early 
stage EOC (Colombo et al., 2019).
Concerns regarding MIS in the staging and debulking of early stage EOC include 
inadequate exposure of the peritoneal surfaces, tumor cell leakage, insufficient 
lymph node dissection, lack of palpable sensation and the risk of port cite metastasis 
(Semaan, Abdallah and MacKoul, 2008; Gallotta et al., 2014). These concerns center 
upon deficient staging, which might lead to the decreased survival of patients. How-
ever, the risks are reduced with adequate preoperative workup, careful patient selec-
tion and a skillful surgical technique. Consequently, the recurrence rate after MIS for 
early stage EOC has been reported to be compatible with that of the conventional 
midline laparotomy (Park et al., 2013). 
Explorative laparoscopy is used in the diagnostic work up of patients with advanced 
stage EOC (Rutten et al., 2012; Zeff, 2018). The aim of the diagnostic procedure is to 
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improve the prognosis of patients by enabling a comprehensive assessment of oper-
ability (probability of complete cytoreduction); intraperitoneal seeding of tumor is 
easily visualized, the procedure might save the patient from an unnecessary laparot-
omy and patients with inoperable disease can directly proceed to NACT without the 
burdensome recovery from laparotomy (Fagotti et al., 2016). Furthermore, cytologic 
samples and tissue biopsies can be collected during the procedure for the accurate 
histological classification of the disease. 
2.1.8.2 Laparotomy
Debulking surgery (PDS or IDS) through midline laparotomy is the cornerstone of 
primary EOC treatment (Benedet et al., 2000). Patients with stage IIIC or less exten-
sive disease are generally eligible for up front debulking, while the feasibility of PDS 
for stage IV disease or bulky tumors should be carefully evaluated to reach the best 
treatment outcomes (Van Meurs et al., 2013). There is moderate evidence indicating 
that women treated with NACT and IDS have a similar overall survival as women 
undergoing PDS (Coleridge et al., 2019). However, PDS should be considered the 
standard treatment for EOC as there is also contradictory results demonstrating 
inferior survival in the NACT group regardless of complete cytoreduction in IDS 
(Gadducci et al., 2017). 
As always in surgery, the extent of the procedure should be balanced with the 
associated increase in morbidity. Modern supportive care enables ultra-radical sur-
gery, in which the range of cytoreduction is extended from the pelvis, omentum and 
lymph nodes to the upper abdomen and multi-visceral resections (e.g. diaphragmatic, 
liver, splenic and gastrointestinal resections) (Lepinay et al., 2019). A recent study 
indicated that the morbidity risk increase with high-complexity surgery, specifically 
with diaphragmatic resection and gastrointestinal anastomosis (six times increased 
risk) and multiple bowel resections (eight times increased risk) (Phillips et al., 2019). 
However, aggressive surgical effort and consequent complete cytoreduction is associ-
ated with survival gain and should be strived for whenever feasible (Aletti et al., 2009). 
2.1.8.3 Medical Treatment
The standard intravenous (i.v.) chemotherapy regimen for all patients with EOC is 
six cycles of paclitaxel (175mg/ m2) combined with carboplatin (AUC 5–6) (Benedet 
et al., 2000). There is strong evidence that also patients with early stage EOC have 
long term survival benefits from i.v. chemotherapy (Lawrie et al., 2015). However, it 
is still uncertain whether the survival benefit outweighs the adverse effects of chemo-
therapy in patients with low grade stage IA disease, and the adjuvant chemotherapy 
of these patients may be omitted (Lawrie et al., 2015). 
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Bevacizumab, an anti-angiogenic agent, increases the progression free survival 
(PFS) of especially high risk EOC patients (stage IV or III + residual tumor) and 
should be included in the primary treatment of these patients (González Martín et 
al., 2019). In addition, bevacizumab have been shown to increase the overall survival 
(OS) of high risk patients in a phase 3 randomized study (Oza et al., 2015). Bev-
acizumab is also validated in the treatment of recurrent EOC, both in a platinum 
sensitive and resistant relapse (Pujade-Lauraine et al., 2014; Aghajanian et al., 2015). 
In addition to bevacizumab, another group of molecular targeted therapy, namely 
PARPi, has recently been introduced in the treatment of EOC. PARPis exhibit syn-
thetic lethality specifically on cancer cells with homologous recombination (HR) 
deficiency, which is present in approximately half of HGSCs (80–90% of all EOCs) 
(Kossaï et al., 2018). Presently, there are three PARPi approved for this intent: olap-
arib, niraparib and rucaparib (Colombo et al., 2019). The strongest clinical evidence 
for the use of PARPis is, at present, in its use as a maintenance therapy after a response 
to platinum-based chemotherapy in the first line setting as well as in the second line 
or higher (Colombo et al., 2019). Similar to bevacizumab, PARPis have been shown 
to increase the PFS of EOC patients and this effect is most notable in, but not limited 
to, patients with a BRCA mutation (Colombo et al., 2019).
The utility of immunotherapy as a treatment modality in EOC is currently being 
explored in clinical trials. The mutation of normal cells to cancer cells is a process 
that takes place daily in every human and consequently, the immune system is highly 
trained in the elimination of cancer cells (Pietzner et al., 2018). Cancer cells have 
three distinct ways of breaching the protection mechanisms: down-regulation of the 
antigen presentation with subsequent impaired tumor cell recognition by T-cells, 
the creation of an immunosuppressive microenvironment and the utilization of the 
safety feature of the host’s immune system called the “immune checkpoint” (Pietzner 
et al., 2018). Immune checkpoints are complex constructs that protect healthy cells 
by blocking T-cells from lethal action despite specific antigen recognition (Pietzner 
et al., 2018). Checkpoint inhibitors, i.e. nivolumab, pembrolizumab, durvalumab and 
tremelimumab, target this mechanism hijacked by cancer cells and consequently 
restore the anti-tumor activity of T-cells (Wang, Liu and Zou, 2019). An initial report 
on the efficacy of nivolumab in EOC treatment presented promising results as nine 
patients of twenty responded to the treatment (Hamanishi et al., 2015). In addition 
to checkpoint inhibitors, the adoptive transfer of ex vivo - expanded tumor-specific 
T-cells and cancer vaccines are being investigated as immunotherapy options in EOC 
(Wang, Liu and Zou, 2019).
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2.2 Serological and Genomic Biomarkers of EOC
2.2.1 Cancer Antigen 125 (CA125)
The CA125 immunoassay was developed and described for the first time in 1983 
(Bast et al., 1983). In the initial report, 1% of 888 healthy individuals had serum 
CA125 levels exceeding 35.0 U/ml and a normal range for serum CA125 was deter-
mined accordingly. The first version of the CA125 assay utilized only OC125 (CA125 
I) as the capture antibody and another epitope group, M11, has since been added 
to the assay (CA125 II) (Duffy et al., 2005).  The assay utilizing M11 and OC125 as 
capture antibodies is the assay generally in use today. The CA125 assay has since its 
development become a well validated biomarker assay in EOC diagnostics, moni-
toring and follow-up, and it is currently the only widely recognized biomarker assay 
used in the clinical setting (Bast, 2010; Pignata et al., 2011; Zhang, Cai and Zhong, 
2011). 
2.2.1.1 The CA125 Molecule and Glycosylation
The CA125 molecule is a large (200–2000 kDa) mucin-type transmembrane glyco-
protein with an extensive amount of N- and O-glycans (249 potential N-glycosyla-
tion and over 3700 O-glycosylation sites) (Saldova et al., 2013). CA125 consists of a 
short cytoplasmic tail, a transmembrane domain and an extracellular domain, which 
contains the binding site of OC125 and M11 (O’Brien et al., 2001). The epithelial 
growth factor receptor signal transduction pathway is linked to the release of CA125 
to the bloodstream (Scholler, Urban and Gene, 2007). The exact function of CA125 is 
poorly understood, but its structure indicates a possible immunological role (O’Brien 
et al., 2001). 
Glycosylation is an enzymatic process that fuses saccharides to other saccharides, 
lipids or proteins (Fuster and Esko, 2005). Deviant glycosylation is a characteristic 
feature in human cancers and initial reports of aberrant glycosylation were published 
over five decades ago (Hakomori and Murakami, 1968). The typical cancer-associ-
ated changes in glycosylation are sialylation, fucosylation, O-glycan truncation and 
N- and O-linked glycan branching (Hakomori, 2002). The aberrant glycosylation of 
serum CA125 in patients with ovarian cancer is particularly notable in N-glycans: 
ovarian cancer patients have increased rates of core-fucosylated bi-antennary mono-
sialylated glycans and decreased rates in mostly bisecting bi-antennary and non-fu-
cosylated glycans compared to healthy controls (Saldova et al., 2013).  As the changes 
in glycosylation are cancer specific, the quantification of glycans with their protein 
backbone is a feasible tool for increasing the diagnostic and prognostic potential 
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of current glycoprotein biomarkers, e.g. CA125 (Pinho and Reis, 2015). Promising 
results have been attained with several biomarkers in other cancers, including breast, 
liver and pancreatic cancer (Matsuura, Kawai and Ilirai, 1993; Okuyama et al., 2006; 
Wi et al., 2016; Terävä et al., 2019). 
2.2.1.2 CA125 in Healthy Women
The serum level of CA125 vary in healthy women and several factors influencing 
the variance of serum CA125 have been identified. Premenopausal women generally 
have higher levels of CA125 (mean value of 18 U/ml) compared to postmenopausal 
patients (mean value of 12.0 U/ml) (Bon et al., 1996). Further, fluctuation in the 
serum CA125 levels have been detected during different phases of the menstrual 
cycle, highest values arising during the menses (McLemore et al., 2012). Elevated 
serum CA125 levels have also been associated with pregnancy (Wang et al., 2018). 
Lower baseline CA125 levels have been detected in women with a history of smok-
ing, regular coffee consumption and hysterectomy (Pauler et al., 2001). In contrast, 
women with a prior non-ovarian cancer diagnosis have been reported to have 
increased baseline serum CA125 levels (Pauler et al., 2001).
2.2.1.3 CA125 and EOC
Elevated serum CA125 levels are detected in approximately 80–90% of patients with 
EOC (Duffy et al., 2005). However, only circa 50% of patients with early stage EOC 
present with elevated serum CA125 levels (Zhang, Cai and Zhong, 2011). Conse-
quently, it has been established that the CA125 assay lacks the required sensitivity and 
specificity for screening purposes (Sölétormos et al., 2016). In the differential diag-
nostic of pelvic masses, the CA125 assay is used as a part of a multimodal approach 
(clinical examination, TVS and serum CA125) for increased accuracy (Sturgeon 
et al., 2008) as elevated serum CA125 is largely unspecific for EOC. Several other 
malignancies, typically adenocarcinomas (e.g. breast, pancreas, endometrial and cer-
vical), express CA125 (Massuger et al., 1997; Liu et al., 2016; Bian et al., 2017; Wang 
et al., 2017). A further limitation of CA125 is its elevation in various non-cancerous 
diseases, most importantly diseases of gynecologic origin (e.g. ovarian cysts, endome-
triosis and inflammations) but also in conditions irritating the peritoneum, pleura or 
pericardium (e.g. liver cirrhosis with ascites and congestive heart failure with pleural 
effusion) (Xiao and Liu, 2003; R. G. Moore et al., 2012; K. H. C. Li et al., 2018). In EOC 
diagnosis,  CA125 is most suited for detecting serous, endometroid and clear cell car-
cinomas and is less frequently elevated in mucinous carcinomas (Duffy et al., 2005). 
The measurement of serum CA125 is the standard method in the treatment 
monitoring and follow-up of EOC (Duffy et al., 2005; Sturgeon et al., 2008). 
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In treatment monitoring, serum samples are optimally drawn 2 weeks before the start 
of treatments and subsequently every 2–4 weeks during chemotherapy (Sturgeon et 
al., 2008). A rising serum value of CA125 correlates with disease progression in 90% 
of patients and persistently elevated CA125 values equal with persistent disease in 
95% of patients (Bast et al., 2005). However, the CA125 assay has its limitations in 
the monitoring of patients with EOC, as small volumes of persistent disease might be 
present in up to 50% of patients regardless of CA125 normalization (Bast et al., 2005). 
Despite its limitations, CA125 is currently the only biomarker used in the treatment 
response evaluation of patients with EOC (John et al., 2011). The prognostic value 
of CA125 has been widely investigated, and the nadir value and rapid normalization 
of serum CA125 have shown prognostic potential (Bast et al., 2005; Van Altena et 
al., 2010; Zeng et al., 2017). It has also been indicated that the preoperative level of 
serum CA125 might be a feasible tool for the assessment of operability (Chi et al., 
2000; Kang et al., 2010), but there have also been contradictory results (Barlow et al., 
2006; Mury et al., 2011). 
The feasibility of serum CA125 measurement in the follow-up of EOC was ques-
tioned in a large multicenter trial, as the authors did not detect a survival benefit 
from an early intervention to asymptomatic, CA125 positive recurrence compared to 
intervention in a later, symptomatic phase (Rustin et al., 2010). There are no published 
studies investigating the feasibility of treating early, asymptomatic recurrence in the 
current era of PARPis and other precision drugs and consequently, the retainment 
from early intervention needs to be re-evaluated. However, follow-up with CA125 is 
currently recommended especially if patients are considered for studies on second 
line treatments, patients do not have regular (3 monthly) follow-up visits/imaging 
studies, secondary surgery is a treatment option in case of recurrence or the patient 
is included in a clinical study (Verheijen et al., 2012). The serum level of CA125 is 
generally elevated approximately 3 months before symptomatic recurrence (Bast et 
al., 2005). 
2.2.1.4 CA125 Glycoforms and EOC
A few approaches have been described in the quantification of aberrantly glyco-
sylated circulatory CA125 in patients with EOC. A microarray-based approach 
measuring two aberrant glycoforms (Neu5Acα2,6GalNAc [STn] and GalNAc [Tn]), 
showed promise in improving the performance of the conventional CA125 assay in 
EOC diagnostics (Chen et al., 2013). A similar, lectin-based, immunoassay approach 
was described in 2016 (Gidwani et al., 2016). The immunoassay utilized macrophage 
galactose-type lectin (MGL) with a nanoparticle component (Gidwani et al., 2016). 
Recently, an analogous assay utilizing Sialyl-Thomsen-nouveau antibody (STn) with 
a nanoparticle component showed increased diagnostic potential in differentiating 
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CA125 from benign and malignant sources (Gidwani et al., 2019). Lectins are a 
family of small proteins with the capability of binding to carbohydrates, which makes 
them putative tools in the exploration of aberrant glycosylation. However, the appli-
cability of lectins has been restricted by their low binding affinity to carbohydrates 
(Gidwani et al., 2020).  Both the CA125-MGL and-STn assays utilized nanoparticles 
to increase the problematically low affinity of lectins and antibodies: a number of lec-
tins or antibodies was fixed onto the nanoparticles to create a reporter with increased 
reactivity while maintaining the original specificity of the lectin/antibody (Gidwani 
et al., 2020). In addition, the polystyrene nanoparticles contain approximately 30000 
fluorescent europium (Eu) chelates, which results in a significant signal amplification 
(Gidwani et al., 2020). Another, non-lectin, approach to glycoprofiling was recently 
described, in which an automated glyprofiling platform showed promising results 
in the diagnosis of EOC (Flaherty et al., 2019). The platform analyzed the glycans 
of six glycoproteins, however, not those of CA125 (Flaherty et al., 2019). In con-
clusion, glycoprofiling of the CA125 molecule is a promising tool in improving the 
conventional CA125 assay and enabling a more cancer specific approach to EOC 
diagnostics. Studies on the prognostic potential of CA125 glycoforms have not been 
previously conducted.
2.2.2 Human Epididymis Protein 4 (HE4)
Human epididymis protein 4 (HE4) is encoded by the WFDC2 gene (chromosome 
20q12–13) and central to its structure is a whey acidic protein (WAP) type four 
disulphide core domain (Bingle, Singleton and Bingle, 2002). The structure of HE4 
is similar to known leukocyte protease inhibitors and it has been suggested that HE4 
might play a role in natural immunity (Bingle, Singleton and Bingle, 2002; Clauss, 
Lilja and Lundwall, 2002). HE4 was initially identified in 1991 by Kirchhoff et al, who 
hypothesized HE4 to be solely expressed by epididymal tissue (Kirchhoff et al., 1991). 
However, more recent studies have shown HE4 immunoreactivity in several other 
tissue microarrays, including the fallopian tubes, salivary glands, pancreaticobiliary 
system and thyroid gland (Galgano, Hampton and Frierson, 2006). Interestingly, the 
variance of serum HE4 is relatively small between the sexes (7% lower serum concen-
tration in males) implying that the majority of circulatory HE4 is derived from other 
sources than the female reproductive organs (Bolstad et al., 2012). The upper 95th 
percentile of 150.0 pmol/L is validated as the cut off for the HE4 assay as reported 
by the assay manufacturer  (Fujirebio Diagnostics Inc, Malvern PA, USA). However, 
a two-threshold system has since been suggested (70.0 pmol/L for premenopausal 
patients and 140.0 pmol/L for postmenopausal patients) as it is acknowledged that 
the serum HE4 levels increase with age (Dochez et al., 2019).
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2.2.2.1 HE4 in Healthy Women
Several physiological and demographical factors affect the concentration of circula-
tory HE4 in healthy women. The effect of age on serum HE4 levels have shown to be 
notable and a study by Bolstad et al described a 37% increase in serum HE4 in women 
aged 60 compared to those of 20 years of age (Bolstad et al., 2012). However, the 
longitudinal HE4 kinetics associated with aging seem to be complex and non-linear, 
modelled by a higher degree polynomial (Bolstad et al., 2012). Similar findings have 
been reported by other researchers, and the most substantial increase in circulatory 
HE4 has been observed in women over the age of 55 and the positive trend continues 
until 80 years of age (Moore et al., 2012; Urban et al., 2012). The association of the 
menopausal status and serum HE4 has been investigated, and currently there is no 
robust evidence on the menopause affecting serum HE4 levels. Moore et al examined 
a subgroup of premenopausal women aged 40 years and older and postmenopausal 
women aged 60 years and less, and detected no difference in the circulatory HE4 levels 
between the groups (Moore et al., 2012). Escudero et al detected a modest elevation 
in the HE4 levels of postmenopausal women compared to premenopausal women, 
however; the difference was not statistically significant (Escudero et al., 2011). Con-
tradictory results have also been reported, as menopausal status was significantly 
affecting the serum HE4 levels in a Chinese population of 618 healthy women (Tian 
et al., 2015). Indeed, more comprehensive studies on the subject are warranted. 
A few studies have been conducted on the kinetics of HE4 during the normal 
menstrual cycle of healthy women and currently the matter is still under debate. 
A recent study detected a significant elevation in circulatory HE4 levels in women 
during ovulation, although the absolute rise in serum HE4 was modest (7.1 pmol one 
day after the luteinizing hormone surge) (Moore et al., 2017). Contradictory results 
were presented by Hallamaa et al in a study, in which no significant changes were 
detected in the serum HE4 levels during the proliferative, secretory, inactive/atrophic 
or menstrual phase of the cycle (Hallamaa et al., 2012). Regarding the effect of preg-
nancy on circulatory HE4, a study on 67 pregnant women showed significantly lower 
HE4 levels compared to non-pregnant controls (Moore et al., 2012). However, the 
longitudinal trend of HE4 during pregnancy was consistent, and HE4 might be a 
feasible biomarker in the triage and monitoring of pelvic masses during pregnancy 
with certain adjustment (Moore et al., 2012; Qu et al., 2016). 
Behavioral factors affecting the circulatory HE4 levels in healthy women include 
smoking, weight and obesity (Qu et al., 2016). Studies have detected 10% lower 
serum HE4 levels in obese women (body mass index 30), and the serum HE4 levels 
in current smokers have been reported to be significantly elevated with 20–30% com-
pared to non-smokers (Bolstad et al., 2012; Urban et al., 2012). Primarily, the deviant 
HE4 concentrations are linked to metabolic changes associated with obesity and the 
inflammatory response in the airways related to smoking (Qu et al., 2016). 
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2.2.2.2 HE4 in non-Ovarian Malignancies
The upregulation of HE4 expression is a typical attribute of carcinogenesis in a vari-
ety of non-ovarian tumors. A comprehensive analysis on the tissue expression of HE4 
was conducted by Galgano et al, and especially endometrial, pancreaticobiliary, lung 
and salivary gland malignancies showed increased HE4 expression profiles (Figure 
2) (Galgano, Hampton and Frierson, 2006). Supportive results were presented in a 
study on gastrointestinal carcinomas, of which specifically stomach and pancreatic 
carcinoma showed increased expression of HE4 (O’Neal et al., 2013). Interestingly, 
the HE4 upregulation in the tumor tissues of several malignancies were comparable 
to the level of HE4 upregulation in serous ovarian carcinoma (Galgano, Hampton 
and Frierson, 2006).
Figure 2. HE4 immunoreactivity in the tumor tissue (%) of non-ovarian malignancies.  
Modified from (Galgano, Hampton and Frierson, 2006).
Increased tissue expression does not systematically translate to elevated levels 
of circulatory biomarkers, but there is increasing evidence on the utility of serum 
HE4 in the diagnostics of several non-ovarian malignancies. Specifically, elevated 
concentrations of HE4 has been detected in the serum of patients with endometrial, 
breast, non-small cell lung cancer (NSCLC) and primary liver cancer (Escudero et 
al., 2011; Gündüz et al., 2016; He et al., 2019). However, the clinical applicability 
of HE4 in non-gynecological malignancies is still to be validated. HE4 has shown 
potential in the diagnosis of endometrial carcinoma (EC), however; the results of 
a recent meta-analysis indicate that the studies on HE4 and EC diagnosis are quite 
heterogeneous and studies with larger, homogeneous cohorts are needed to further 
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elucidate the clinical applicability of HE4 (Li et al., 2018). Additionally, EC is gener-
ally diagnosed at an early stage due to specific symptoms (Cymbaluk-Płoska et al., 
2017), which limits the need for diagnostic markers. 
2.2.2.3 HE4 and EOC
A systematic overexpression of HE4 has been associated with EOC; however, the 
upregulation of HE4 expression varies between the different histotypes of the disease 
(Figure 3) (Galgano, Hampton and Frierson, 2006). Overall, HE4 has shown to be 
a feasible EOC biomarker, as the upregulated tissue expression is well translated to 
increased levels of circulatory HE4 in EOC patients (Hellström et al., 2003). Similar 
to the HE4 tumor tissue expression profiles, highest serum HE4 concentrations have 
been reported in serous carcinomas, while the serum HE4 concentration is generally 
low in mucinous carcinomas (Galgano, Hampton and Frierson, 2006; Kristjansdottir 
et al., 2013).  
Figure 3. HE4 immunoreactivity in the tumor tissue (%) of the different EOC histotypes. 
Modified from (Galgano, Hampton and Frierson, 2006).
The initial study on the diagnostic potential of serum HE4 in EOC was con-
ducted by Hellström et al in 2003, and subsequently, several prospective studies have 
confirmed the introductory findings (Moore et al., 2008; Abdel-Azeez et al., 2010; 
Holcomb et al., 2011; Jacob et al., 2011; Van Gorp et al., 2011; Chan et al., 2013). 
The area under the curve (AUC) of HE4 has been reported to vary from 0,86 to 0,93 
between studies in the diagnosis of EOC (Moore, Brown, Miller, Skates, et al., 2008; 
Holcomb et al., 2011; Jacob et al., 2011; Van Gorp et al., 2011; Chan et al., 2013). 
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However, there is some heterogeneity in the control groups used, as some studies 
included healthy controls and others compared EOC patients to those with a benign 
pelvic mass, and consequently, the AUCs reported are not completely comparable. 
Based on these previous studies, the diagnostic performance of the CA125 and HE4 
assays seems to be similar in advanced EOC (no significant differences in the ROC 
curve comparisons). Interestingly, Moore et al and Jacob et al reported HE4 to be 
valuable in the diagnosis of early stage EOC, with a significantly higher sensitivity 
compared to CA125 (p < 0.001) (Moore et al., 2008; Jacob et al., 2011). However, 
contradictory results have also been reported (Kristjansdottir et al., 2013). 
Moreover, there is some evidence on the superiority of HE4 over CA125 in 
dividing patients with tumors of borderline malignancy (BOT) from EOC, but the 
results are conflicting (Holcomb et al., 2011; Jacob et al., 2011; Wang, Tao and Ying, 
2019). As HE4 is generally not expressed in benign gynecologic diseases, specifically 
endometriosis (Huhtinen et al., 2009; Zapardiel et al., 2016), it is a feasible auxiliary 
biomarker in the differential diagnosis of pelvic masses. The most prevalent source 
of falsely elevated serum HE4 concentrations is chronic kidney disease, and elevated 
circulatory HE4 concentrations are already measured at mild levels of kidney failure 
(eGFR 60–89 mL/min/1.73m2) (Nagy et al., 2012). 
There is some controversy on whether the longitudinal kinetics of serum HE4 is 
in concordance with the treatment outcomes of patients and the kinetics of CA125. 
There are two studies addressing this matter, of which the first one was conducted 
in a proof-of-concept manner, including 11 patients with consistent dynamics of 
HE4 throughout the treatment regimen (Hynninen et al., 2011). The other study 
conducted by Ferraro et al evaluated a heterogeneous cohort of 43 patients, in which 
HE4 was not as reliable as CA125 in the treatment monitoring and follow-up of OC 
(Ferraro et al., 2018). However, the cohort consisted of partly non-epithelial ovarian 
malignancies and included patients with renal impairment, which naturally influ-
enced the results.
Studies on the prognostic utility of serum HE4 have been conducted with incon-
sistent results. A recent meta-analysis concluded that a high preoperative HE4 level 
might be a predictor of poor OS and PFS, however, the 14 studies included in the 
analysis were quite heterogeneous and the matter needs to be studied further (Yuan 
et al., 2018). A handful of studies have evaluated the association of preoperative HE4 
levels to the amount of residual disease with promising results. Angioli et al proposed 
a preoperative HE4 cut off of 262.0 pmol/L, which discriminated patients with sub-
sequent complete cytoreduction from those with a suboptimal amount of residual 
disease with a sensitivity and specificity of 86.1% and 89.5%, respectively (Angioli et 
al., 2013). A similar analysis was conducted by Braicu et al, in which the preoperative 
HE4 <235.0 pmol/L predicted optimal cytoreduction with a sensitivity of 76.6% and 
a specificity of 47.3% (Braicu et al., 2013). However, the sensitivity of diagnostic lap-
aroscopy has been reported to be 71% and 95% within studies, with the accuracy of 
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90% (Fagotti et al., 2005; Van De Vrie et al., 2019). Obviously, diagnostic laparoscopy 
is an invasive procedure, and the measurement of serum HE4 in combination with 
a preoperative CT scan might be a feasible auxiliary method in the evaluation of up 
front cytoreductibility. Although the results on the association of preoperative HE4 
and residual disease are indicative of HE4 being a potential indicator of tumor load, 
there is currently no studies in which the preoperative serum HE4 concentration 
is directly compared to the tumor load assessed during surgery and/or by CT scan. 
One study has evaluated the association of the HE4 nadir to different end points, 
specifically to treatment response and PFS (Vallius et al., 2017). Interestingly, lower 
HE4 nadir levels were associated with a better response to treatment and a longer PFS 
(Vallius et al., 2017). 
A few studies have addressed the utility of HE4 in the detection of EOC relapse 
(Capriglione et al., 2017). Anastasi et al conducted a study, in which elevated serum 
HE4 concentrations were detected with a lead time of 5–8 months to serum CA125 
preceding the detection of recurrent disease (Anastasi et al., 2010). The sensitivity 
and specificity of the combination of HE4 and CA125 in the detection of recurrent 
OC was evaluated in one of the studies with interesting results: a sensitivity of 76% 
(vs 35% with CA125 alone) and a specificity of 100% (vs 59% with CA125 alone) 
was reached (Plotti et al., 2012). In addition, HE4 showed potential in a recent study, 
in which 7/8 patients with CA125-negative disease had positive serum HE4 levels 
at disease follow-up and progression (Plotti et al., 2019). Studies on the prognostic 
value of HE4 at progression have not been published to date.
Currently, there is no clear consensus on the benefit of including HE4 in the 
treatment monitoring and follow-up of patients with EOC and consequently, the 
routine measurement of HE4 is not recommended to this end (Colombo et al., 2019). 
Studies with larger, homogeneous cohorts are needed for the further exploration of 
the utility of serum HE4 measurement during EOC treatment and recurrence.
2.2.3 Circulating Tumor DNA (ctDNA)
The presence of cell free DNA (cfDNA) in the human bloodstream was initially 
described in 1948 (Mandel and Metais, 1948). It has since been detected that patients 
with cancer have elevated levels of circulatory cfDNA, of which the majority is ctDNA 
(Stroun et al., 1989; Barlebo Ahlborn and Østrup, 2019). There are three different 
sources to cfDNA in the circulatory compartment of cancer patients (healthy cells, 
tumor cells and tumor microenvironmental cells), which need to be acknowledged 
when evaluating the cfDNA burden of a patient (Thierry et al., 2016). Further, the 
amount of cfDNA is dependent not only on its release from cells but also on its 
clearance from the circulatory system. The data on cfDNA clearance is limited, but a 
study on fetal cfDNA suggests a biphasic clearance of cfDNA: the initial rapid phase 
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had a half time of approximately 1h, and the subsequent slower phase had a half 
time of circa 13h (Yu et al., 2013). However, data on ctDNA clearance in patients 
with colorectal cancer showed a monophasic ctDNA clearance half time of 114min 
after complete cytoreduction (Diehl et al., 2008). The elimination of cfDNA occurs 
mainly through enzymatic degradation in the bloodstream (DNase I, plasma factor 
VII–activating protease, and factor H), entrapment and elimination in the liver and 
spleen, and secretion from the kidneys (Yu et al., 2013; Stephan et al., 2014; Kus-
tanovich et al., 2019). Tumor cells leak their DNA to the extracellular compartment 
through apoptosis, necrosis, phagocytosis, oncosis, and active secretion (Thierry 
et al., 2016). The fragmentation of ctDNA has shown to be high compared to the 
cfDNA of healthy individuals, and the majority of ctDNA fragments are below 145 
bp (Mouliere et al., 2011; Thierry et al., 2016). The increasing genomic analyses of 
cfDNA have shed light on the presence of leukemia-associated genetic mutations 
in the circulatory system of otherwise healthy individuals (Luis et al., 2019). This 
phenomenon, clonal hematopoiesis, is strongly associated with aging and is linked 
to mutations within long-lived hematopoietic stem cells (Luis et al., 2019). Clonal 
hematopoiesis is a possible confounding factor in the ctDNA analyses and should be 
acknowledged especially in the elderly.
Although cfDNA can be viewed as a passive component in the circulatory 
system, there is increasing evidence of its functional role in intercellular communi-
cation, transformation of other cells and immunomodulation (Thierry et al., 2016; 
Kustanovich et al., 2019). Most intriguing from an oncologic perspective is the ability 
of ctDNA to foster tumor progression by transfecting healthy cells and subsequently 
forming distant metastases (Trejo-Becerril et al., 2012). These studies suggest that 
ctDNA might be a feasible therapeutic target in addition to its potential as a diagnos-
tic tool. 
2.2.3.1 CtDNA as a Liquid Biopsy Component in Cancer
CtDNA is typically extracted from blood and it carries information of the genetic 
and epigenetic aberrations of the tumor (Kustanovich et al., 2019). Different detec-
tion technologies can be utilized, including next generation sequencing (NGS), 
digital-PCR platforms, real-time PCR platforms, mass-spectrometry technology and 
detection of hypermethylation in ctDNA (Elazezy and Joosse, 2018). 
Studies measuring the serum or plasma concentration of ctDNA in cancer 
patients generally link the amount of ctDNA to tumor volume either by imaging 
studies or disease stage (Reece et al., 2019). Nevertheless, the early detection of 
malignancies with ctDNA has proven to be difficult, as early stage tumors shed 
less DNA (50% of patients have detectable plasma ctDNA vs 82% of patients with 
metastasized disease) and consequently, the background noise of regular cfDNA 
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is emphasized  (Bettegowda et al., 2014). Another recent study reported 71% and 
59% rates of ctDNA positive patients with early stage colorectal and breast cancer, 
respectively (Phallen et al., 2017). Currently, the sensitivity of ctDNA as a screening 
tool is inferior to conventional screening methods (Barlebo Ahlborn and Østrup, 
2019). Although the feasibility of ctDNA plasma concentration measurement alone 
in early cancer diagnostics is debatable, its diagnostic potential might be improved 
by including analyses of ctDNA gene methylation to detect epigenetic deregulation 
of genes (Elazezy and Joosse, 2018). The dualistic approach yielded promising results 
in a recent proof-of-concept study on renal cell carcinoma, in which a diagnostic 
accuracy of 100% was reached (Skrypkina et al., 2016). 
The quantification of the ctDNA concentration has been studied in the detection 
of  minimal residual disease (MRD) after surgery and in cancer relapse (Reece et al., 
2019). However, a more advantageous method for detecting MRD and disease relapse 
is currently thought to be the mutation tracking of ctDNA (Elazezy and Joosse, 2018). 
Several studies have been conducted on ctDNA mutation dynamics perioperatively 
and in relapse (Tie et al., 2016; Ng et al., 2017; Murray et al., 2018; Chen et al., 2019). 
These studies on colorectal and lung cancer indicate that the detection of ctDNA 
after apparent complete cytoreduction surgery is associated with MRD and subse-
quent relapse (Tie et al., 2016; Ng et al., 2017; Murray et al., 2018). Interestingly, there 
were patients in two of these studies that had persistently elevated plasma ctDNA 
without clinical or radiological indication of recurrent disease in the frame of the 
follow-up period (Tie et al., 2016; Ng et al., 2017). However, late recurrence remains 
an explanation of the phenomenon. 
The possibilities of ctDNA in the monitoring of cancer treatment have attracted 
scientific interest, as more precise tools enable the discontinuation of ineffective ther-
apy and allows the implementation of more suitable ones. With novel precision drugs, 
a comprehensive knowledge of the tumor mutation profile is needed for the design of 
optimal treatment plans. However, inaccuracies might occur with traditional tissue 
biopsy, as tumors often contain subclones and mutations may vary between metasta-
ses (Reece et al., 2019). In addition, the mutation profile of the tumor might progress 
and change during treatment resulting in treatment resistance (Ahlborn et al., 2018). 
Recent studies have indicated a good correlation (70–90%) between the tumor muta-
tion profile attained from tissue biopsy and that of liquid biopsy (Phallen et al., 2017; 
Chen et al., 2019). Consequently, longitudinal tracking of the ctDNA mutation pro-
file has been proven feasible in detecting and tracking therapy resistance in colorectal 
and other solid cancers (Misale et al., 2012; Ahlborn et al., 2018). However, there are 
limitations in the utilization of liquid biopsy in the mapping of the tumor mutation 
profile, e.g. the biopsy might show low levels of or excessively fragmented ctDNA, 
which results in a substandard picture of the tumor mutation profile. An overview of 
the advantages and disadvantages of conventional tissue biopsy and liquid biopsy are 
presented in Table 4.
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Table 4. Advantages and disadvantages of tissue biopsy and liquid biopsy.  
Modified from (Barlebo Ahlborn and Østrup, 2019).
Type of biopsy Advantages Disadvantages
Solid (tissue) Standard detection method Invasive and expensive
Possibility of cytopathology Possible complications
High concentration of tumor cells Not real-time detection
Identification of mutation relevant 
for targeted therapies
Do not capture heterogeneity 
(unless multiple biopsies)
Possibility for RNA (transcriptome 
profiling and gene-expression 
analysis) and protein analysis
Some tumors are not accessible
Liquid (ctDNA) Minimally invasive (e.g. blood, 
saliva urine, CSF)
RNA and protein analyses  
not possible 
Minimal procedural risk Short DNA-fragment length
Repeatable Low levels of ctDNA
Real-time measurement Challenges with pre-analytical 
factors
Marker of therapy effect and 
surgery
Limited clinical applications
Possibility of capturing tumor 
heterogeneity
Individual levels between patients 
and cancer types
Abbreviations: CSF: cerebrospinal fluid
2.2.3.2 CtDNA and EOC
EOCs are known to be histologically and molecularly heterogeneous, and espe-
cially HGSC is characterized by frequent chromosomal instability (Cancer Genome 
Atlas Research Network et al., 2011; Giannopoulou, Kasimir-Bauer and Lianidou, 
2018).  Recent studies on the ctDNA of EOC patients have been directed at chromo-
somal abnormalities, somatic mutations and aberrant methylation (Giannopoulou, 
Kasimir-Bauer and Lianidou, 2018). So far, the studies on early stage EOC diagnosis 
with ctDNA have presented ambivalent and complicated results: several studies show 
good discrimination in the cfDNA of controls and cancer patients (Zhang et al., 2013; 
Cohen et al., 2016; Widschwendter et al., 2017); however, contradictory results have 
also been reported  (No et al., 2012). A recent meta-analysis including the data of 
1125 patients and 1244 controls (22 studies) showed a pooled area under the curve 
(AUC) of 0.896 for ctDNA, which is similar to the AUC of CA125 (0.883) (Li et 
al., 2019). However, the comprehensive differences in methodology and laboratory 
environments were reported as significant confounding factors. Although there is 
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increasing evidence of the utility of ctDNA in EOC diagnostics, standardized and 
prospective studies are warranted for a more robust level of evidence.
As in other solid tumors, the longitudinal tracking of ctDNA has been demon-
strated to be a beneficial method in the detection of MRD during the treatment and 
asymptomatic relapse of patients with EOC (Forshew et al., 2012; Martignetti et al., 
2014; Pereira et al., 2015; Parkinson et al., 2016; Kim et al., 2019). Pereira et al demon-
strated that the serial measurement of ctDNA during treatment performed similarly 
as the conventional CA125 monitoring. In addition, elevated plasma concentrations 
of ctDNA were detected on average 7 months before detectable relapse with radio-
logic or conventional serologic methods (Pereira et al., 2015). A case study showed 
that longitudinal ctDNA tracking is a promising tool in reveling new tumor-specific 
gene fusions, which might enable the use of precision drugs in selected patients 
(Martignetti et al., 2014). Further, the authors concluded that ctDNA monitoring 
results were consistent with the presence of residual disease (Martignetti et al., 2014). 
Parkinson et al studied the concentration of tumor protein 53 (TP53) mutations in 
EOC patients and similarly suggested that the ctDNA load correlates well with tumor 
volume. The longitudinal tracking of ctDNA also gave prognostic information, as 
the decrease of <60% in the TP53 mutant allele fraction (MAF) after the initial cycle 
of chemotherapy predicted disease relapse within 6 months (Parkinson et al., 2016). 
A recent study also evaluated the utility of TP53 mutation tracking as a modality in 
EOC treatment monitoring, and concluded that the longitudinal tracking of TP53 is 
clinically efficient and outperforms CA125 (Kim et al., 2019). Currently, the strongest 
evidence on the clinical utility of ctDNA in patients with EOC lies in the treatment 
monitoring of EOC and detection of MRD (Asante et al., 2020).
The selective pressure induced by conventional chemotherapy (e.g. platinum 
agents) or even targeted drugs, such as PARPis, might eventually result in the trans-
formation of EOC cells through additional gain or reversion of genetic aberrations 
(Asante et al., 2020). A recent study detected several mutations associated with treat-
ment resistance in the plasma ctDNA of three EOC patients (RB1, MTOR, ZEB2, 
CES4A, BUB1 and PARP8) after they received treatment with either cisplatin, pacl-
itaxel or liposomal doxorubicin (Murtaza et al., 2013). Similar results were reported 
in an earlier study, in which a de novo mutation of the tyrosine kinase domain (exon 
21) of EGFR was detected in the ctDNA of one patient with EOC (Forshew et al., 
2012). An essential initiator in both platinum and PARPi resistance in BRCA-mutant 
EOC is the reverse mutation of the BRCA gene (Lin et al., 2019). A BRCA reverse 
mutation results in the regained function of the opening reading frame and a sub-
sequent functional homologous recombination repair (Christie and Bowtell, 2017). 
Interestingly, a recent study detected the BRCA reverse mutations to be generally 
subclonal, which indicates a multifactorial resistance mechanism or that the resistant 
cancer cells might interact with and protect more sensitive cells (Christie and Bow-
tell, 2017). However, these studies on the potential of ctDNA in guiding treatment 
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decisions utilized panels with a specific set of genes (a few to tens of genes), which 
decreases the probability of detecting relevant mutations. In conclusion, the genetic 
factors behind acquired treatment resistance in EOCs are heterogeneous, and further 
studies on the utility of ctDNA tracking in mutation-driven resistance are needed to 
elucidate these mechanisms. 
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3 Aims of the study
The principal aim of this thesis was to evaluate the potential of novel biomarkers 
in ovarian cancer diagnosis, treatment monitoring and follow-up. In addition, we 
aimed at paving the way for future, more comprehensive validation studies on these 
biomarkers.
The distinct aims of the study were:
1. To evaluate the applicability of CA125 glycoform measurement in the 
differential diagnostics of pelvic masses.
2. To examine the utility of longitudinal CA125 glycoform measurement 
in the treatment monitoring and follow-up of HGSC. 
3. To analyze comprehensively the feasibility of serum HE4 measurement 
in the treatment monitoring and prognostic stratification of HGSC.
4. To evaluate the benefit of ctDNA tracking in the timely identification of 
therapy resistant HGSC.
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4 Materials and Methods
4.1 Patients, Study Design and Protocol
The study population was comprised of two cohorts prospectively collected in ter-
tiary referral hospitals in Finland (I, II, III, IV) and Norway (I). In Turku University 
Hospital, Finland, patients have been recruited since 2009 for a clinical study on EOC 
biomarkers (ClinicalTrials.cov identifier: NCT01276574) and patients recruited 
between 2009 and 2019 were included in the current study. Women with endome-
triosis and healthy controls recruited for the ENDOMET study were included in the 
benign control group in the Study I (ClinicalTrials.cov identifier NCT01301885). The 
Norwegian cohort was recruited at the Oslo University Hospital during 2012–2015. 
  The inclusion criteria of the study were histologically confirmed EOC (I, II, III, 
IV), a benign gynecologic disease (I) and age of majority (I, II, III, IV). In addition, 
all patients included in Study II and III had at least three longitudinal serum sam-
ples taken during treatment. In addition, specific inclusion criteria in Study III was 
normal serum creatinine and/or glomerular filtration rate. The mean BMI of the 
patients included in Study III was 26.49 kg/m2. The specific characteristics of the 
study populations are presented in Table 5. 
The diagnosis of EOC was based on a clinical examination, TVS, serum bio-
marker levels (CA125 and HE4) and a CT scan, and the diagnosis was histologically 
confirmed with tissue biopsies. Baseline study serum and plasma samples were 
drawn at the time of diagnosis, prior to any surgical or oncological interventions. 
Patients underwent a diagnostic laparoscopy and a treatment decision of either PDS 
or NACT was made by a team of experienced gynecologic oncologists. The amount 
of residual disease after cytoreductive surgery was evaluated by the operating gyne-
cologic oncologist.
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Table 5. Patient characteristics per study.
Study I Study II Study III Study IV
N (EOC) 232 122 143 12
N (benign) 317 0 0 0
N (healthy) 36 0 0 0
FIGO (2014)
I 50 2 0 0
II 10 3 1 1
III 122 77 85 9
IV 43 40 57 2
Histology
HGSC 158 122 143 12
LGSC 24 0 0 0
Clear cell 15 0 0 0
Endometroid 23 0 0 0
Mucinous 12 0 0 0
In the Turku cohort, the tumor spread in the abdominal cavity and retroper-
itoneum was carefully assessed, and a previously described disease dissemination 
score was calculated (Table 6) (II, III) (Isoviita et al., 2019). Patients were divided 
into a low tumor load group (dissemination score 0–12) and a high tumor load group 
(dissemination score 13–21). Platinum- and taxane-based chemotherapy was rou-
tinely administered; however, 16 patients received single agent carboplatin because of 
frailty. Longitudinal serum/plasma samples were collected in the Turku cohort before 
each cycle of chemotherapy during primary treatment and at follow-up visits to the 
outpatient clinic approximately every 3–6 months (II, III, IV). 
We determined the concentrations of serum CA125 and its glycoforms (CA125-
MGL and -STn) from the baseline samples of patients with confirmed EOC, benign 
gynecologic diseases (benign tumors, adnexal torsion, pelvic inflammatory disease 
and endometriosis) and healthy controls (I). In patients with HGSC, longitudinal 
serum CA125, HE4, CA125-MGL and -STn measurements were done from samples 
collected during primary chemotherapy, follow-up and until first progression (II, 
III). Longitudinal plasma samples acquired from 12 HGSC patients were used in the 
identification of actionable ctDNA mutations (IV). 
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Table 6. Disease dissemination score, range 0–21. Modified from (Isoviita et al., 2019).
Points
Anatomic location 0 1 2 3
Pelvic carcinomatosis No Yes
Subdiaphragmatic surface carcinomatosis No Yes
Carcinomatosis around the peritoneal cavity No Yes
Small bowel mesentery carcinomatosis No Yes
Small bowel mesentery retraction No Yes
Large bowel mesentery carcinomatosis No Yes
Small bowel serosa carcinomatosis No Yes
Large bowel serosa carcinomatosis No Yes
Invasion to bowel mucosa No Yes
Largest omental nodule, cm - <2 2–5 >5
Largest right ovary nodule, cm - <10 ≥10
Largest left ovary nodule, cm - <10 ≥10
Pelvic lymph node metastasis, suspected No Yes
Para-aortic lymph node metastasis, suspected No Yes
Spleen metastasis No Yes
Invasion to abdominal wall No Yes
Invasion to liver surface No Yes
4.2 Laboratory Methods
4.2.1 CA125 (I, II, III)
Venous whole blood samples (10ml) were collected into serum separation tubes. 
Samples were incubated for 30–60 minutes at room temperature and centrifuged for 
15 minutes. Serum was separated and stored in -70 – -80 °C. The serum CA125 
values (U/ml) for the Turku EOC cohort and benign controls were determined using 
a clinically well-established ECLIA method on the Cobas e 601 instrument or a Mod-
ular E170 automatic analyzer (linearity 2.0–5000.0 U/ml, inter-assay coefficient of 
variability, CV%, 0.7–3.1 and intra-assay CV% 1.8–6.5) (Roche Diagnostic GmbH, 
Mannheim, Germany). The Oslo EOC cohort and endometriosis controls were 
measured manually using a CA125 EIA kit (linearity 1.5–500.0 U/ml, inter-assay 
CV% 3.1–4.0 and intra-assay CV% 2.9–4.4) (Fujirebio Diagnostics Inc., Malvern, PA, 
USA) in accordance with the guidelines of the manufacturer. The correlation of the 
assays is good, and they have comparable slopes, r=0.989 (y=0.99 + 5.3) (Fujirebio). 
Moreover, the assays have the same cut-off of 35.0 U/ml.
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4.2.2 CA125-MGL and -STn (I, II)
The measurements of serum CA125-MGL and -STn with in-house time resolved 
fluorometry (TRF) immunoassays were performed by a blinded investigator in an 
identical fashion. Firstly, biotinylated capture Ov185 monoclonal antibody or Ov185 
F(ab’)2 (50 ng/30 µl /well) were immobilized to streptavidin-coated low-fluorescence 
microtiter wells (Kaivogen Oy, Turku, Finland) in the assay buffer for 60 min at room 
temperature (RT) without shaking. After washing twice, 25 µl of standard (OVCAR-3 
cell line purified CA125) or diluted serum sample was added in triplicates and incu-
bated for 60 min at RT with shaking. Samples were diluted 1:5 and 1:10 in buffer 
solution for CA125-MGL and CA125-STn, respectively. After washing twice for 
CA125-MGL and four times for CA125-STn, the captured CA125 antigen was incu-
bated with the Eu+3-chelate-doped Fluoro-MaxTM polystyrene nanoparticles (NPs) 
(Seradyn Inc., Indianapolis, IN) conjugated with human lectin-MGL (1×107 /25 µl 
/well) or with STn-specific antibody (5×106/25 µl /well) for 90 minutes at RT with 
shaking. After incubation, the wells were washed six times with wash buffer. The 
time-resolved fluorescence for Eu+3 was then measured from dry wells using Vic-
torTM 1420 Multilabel counter. The linearity of the CA125-STn assay was 0.0–500.0 
U/m and the intra-assay CV% was <10.0. The linearity of the CA125-MGL assay was 
0.0–100.0 U/ml and the intra-assay CV% was <15.0. The inter-assay CV% for both of 
the assays was <20.0. The principle of the assays is schematically shown in Figure 4.
Figure 4. Schematic pictures of A) the conventional CA125 immunoassay, in which the capture 
and tracer monoclonal antibodies detect protein epitopes of CA125 and B) the CA125-MGL 
and -STn assays, in which the lectin or antibody coated nanoparticles bind to cancer specific 
CA125 glycan structures.
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4.2.3 HE4 (III)
Venous whole blood samples (10ml) were drawn into serum separation tubes. Sam-
ples were incubated for 30–60 minutes at room temperature and centrifuged for 15 
minutes. Serum was separated and stored in -70 – -80 °C. Samples were thawed to 
+4 °C prior to analyses. The serum HE4 concentrations were determined with the 
EIA method according to the instructions provided by the manufacturer (linearity 
20.0–1500.0 pmol/L, inter-assay CV% < 3.2 and intra-assay CV% < 3.5) (Fujirebio 
Diagnostics Inc., Malvern, PA, USA).
4.2.4 CtDNA (IV)
Venous whole blood (2 x 10ml) samples were drawn into EDTA tubes, shaken 8–10 
times and centrifuged for 10 minutes at 2000 x g. The plasma was separated and 
centrifuged further for 10 minutes. The above-mentioned initial processing of the 
samples was done within a timeframe of 30 minutes from the phlebotomy. The 
plasma samples were aliquoted and stored at -80 °C. 
Tissue and ascites samples for the evaluation of ctDNA and tumor tissue DNA 
correlation were collected during diagnostic laparoscopy and debulking surgery, and 
samples from the ovary and omentum were promoted. Ascites samples were analyzed 
for patients with a recurrent disease if tumor tissue samples were not evaluable. The 
extraction of the tissue DNA was done with the AllPrep DNA/RNA kit (Qiagen) at 
the University of Turku. Whole blood buffy coat samples for the detection of germline 
mutations were taken at baseline and the DNA was extracted by Auria biobank. 
Plasma samples with sufficient concentrations and quality of DNA were sent to 
BGI Genomics (BGI Europe A/S, Denmark) for library preparation and sequencing. 
The OseqTM ctDNA solid tumor panel with 508 actionable genes were utilized for the 
mutation tracking of ctDNA. The samples were subjected to 1000X coverage. Tissue 
and blood cell (germline) samples were similarly sequenced at BGI Genomics and 
the samples were subjected to 200X coverage. BGI is a provider of genomic sequenc-
ing and proteomic services with over 20 years of experience in the field.
The analysis pipeline is presented in Figure 5. Variant detection and filtering 
were performed in Anduril (Ovaska et al., 2010), a bioinformatics workflow opti-
mized for large data sets. Somatic single nucleotide variants (SNVs) were detected 
from mapped and cleaned sequencing data with MuTect2. Matched tumor-normal 
pairs and a panel of normals were used for the filtering of systematic artifacts of 
sequencing. All SNVs and indels were reported as variant allele frequency (VAF), 
to achieve a more robust measurement of sequencing depth and DNA content than 
read counts. Variant annotations were made in Annovar (Wang, Li and Hakonar-
son, 2010) with the databases RefSeq (O’Leary et al., 2016), COSMIC (Forbes et al., 
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2017) and dbSNP, and the CADD functional scores (Kircher et al., 2014). The inclu-
sion criteria for variants were 1) at least three existing reads supporting the variant 
allele and a VAF of >0.01 in at least one sample 2) a minimum coverage of 100 in 
plasma and 30 in tumor tissue samples and 3) a matched blood control sample with 
a minimum coverage of 30, VAF <0.01 and a maximum of 2 reads supporting the 
variant allele. Further mutation filtering included the detection of likely spurious 
mutations by identification of clusters of variants shared by at least three patients 
and not previously reported in databases. A CADD score filter (only mutations 
with a score of >15) was used to exclude non-pathogenic mutations. The detection 
of copy number alterations (CNAs) were performed with PanelDoc (http://github.
com/ammawla/PanelDoC) and CNVPanelizer (http://bioconductor.org/packages/
CNVPanelizer/). PanelDoc was chosen for initial CNA detection and calling, as it 
showed higher sensitivity and correlation than CNVPanelizer in low-purity plasma 
samples. Consequently, CNVPanelizer was used for the verification of the calls. This 
procedure ensured that the CNA calls were not based on errors in the PanelDoc 
software. A read depth ratio of 0.694 was considered as the upper threshold for loss 
of function and 1.652 was similarly considered the lower threshold for gain. The 
SNP array analyses and targeted sequencing results of each patients CNA profiles in 
plasma and tissue samples were compared. This procedure ensured the presence and 
quantity of ctDNA in the plasma samples. CNAs previously acknowledged as action-
able in treatment related toxicity, drug sensitivity and resistance were prioritized. The 
portion of ctDNA (tumor content) in plasma cfDNA was determined by tracking the 
TP53 mutation VAF. In patients with a tissue TP53VAF below 40%, other somatic 
mutations were used for the tumor content estimate. The tracking of longitudinal 
mutation changes was done by identifying the largest proportion of significantly 
decreased variants during chemotherapy.
Putative, clinically actionable mutations acknowledged by ESCAT (the European 
Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets) 
were validated through immunohistochemistry and in situ hybridization in patients 
with the existing mutations in tumor tissue (ERBB2 amplification and/or mTOR 
pathway activation). 
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Figure 5. Analysis pipeline for detection of mutations and CNAs. From the Study IV.
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4.3 Definitions
The clinically established cut off of 35.0 U/ml was used for the conventional CA125 
assay. Cut offs determined in earlier studies were used for the CA125-MGL and -STn 
assays: 2.0 U/ml and 10.0 U/ml, respectively (I) (Gidwani et al., 2016, 2019). 
Complete cytoreduction was defined as 0mm residual disease. The nadir value 
was defined as the lowest conventional serum CA125 value during primary treat-
ment or within 3 months after treatment. The response to primary treatment was 
determined according to the Response Evaluation Criteria in Solid Tumors (RESIST) 
version 1.1 criteria (John et al., 2011). The response was evaluated after the con-
clusion of primary treatment and it was based on a clinical examination, a CT scan 
and the serum CA125 level. Patients were classified as complete responders, partial 
responders or to have stable or progressive disease. Disease progression was deter-
mined with serological and/or radiologic criteria also in accordance with the RESIST 
1.1 guidelines (John et al., 2011). Progression free survival (PFS) was calculated from 
diagnosis to relapse detection.
4.4 Statistical Analyses
The statistical analyses were run on R (Version 3.3.3.) and IBM SPSS software (IBM 
Corp. Released 2017. IBM SPSS Statistics for Macintosh, Version 25.0. Armonk, NY: 
IBM Corp). P < 0.05 was considered statistically significant in all analyses.
4.4.1 Study I
Initially, a sample size calculation was made to ensure a sufficient statistical power 
for the study. The calculation was done for both the CA125-MGL and -STn assays, 
and an appropriate statistical power of 80% was reached. The medians, 25th and 75th 
quartiles of the Turku and Oslo cohorts were compared, and they were combined for 
further analyses, as the behavior of the biomarkers were similar in the two cohorts. 
An age bias was detected, and linear regression was utilized for all biomarker assays 
in order to correct for the age-related trends. The normality of the biomarker values 
in different diagnostic groups were assessed visually and statistically with the Shap-
iro-Wilk test. A logarithmic transformation was made to correct for the skewness 
of the data. The Levene’s test was run to evaluate the equality of variances in the 
biomarker levels of different diagnostic groups. The one-way analysis of variance 
(ANOVA) test was then used to compare the differences in means between diagnos-
tic groups. The confidence intervals were also assessed visually. Multiple compari-
sons were performed with the Tukey’s honest significant difference (HSD) test or the 
Games-Howell test, according to the homogeneity of variances. 
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To evaluate the diagnostic potential of the biomarkers, we generated receiver 
operating characteristic (ROC) curves in different subgroups. The areas under the 
curves (AUCs) were compared with the DeLong method (DeLong, DeLong and 
Clarke-Pearson, 1988). In addition, sensitivities for each biomarker assay were calcu-
lated at a fixed specificity of 90% to further examine the diagnostic feasibility of the 
markers. 
4.4.2 Study II
The longitudinal dynamics of the biomarkers during treatment were evaluated 
separately in patients treated with PDS and NACT. The medians, 25th and 75th 
quartiles were similar in both of the treatment arms and the groups were combined 
for the subsequent analyses. We made a logarithmic transformation to correct for 
the non-gaussian skewness of the data, and baseline and preoperative biomarker 
values were compared to different end points (tumor load, residual disease, treat-
ment response, PFS and OS) with the one-way ANOVA and t tests. Nadir values 
were determined for each biomarker assay and the optimal nadir cut offs to PFS were 
measured from ROC curves with the Youden index method (Youden, 1950). PFS was 
dichotomized as progression vs. no progression, and the median follow-up in the 
progression free group was 19.6 months. We evaluated the correlation of the nadir 
values to PFS with Kaplan-Meier survival curves, and the statistical significance was 
benchmarked with the log rank test and the Cox’s proportional hazards model. Clin-
ically relevant factors were included in the multivariate model in a stepwise fashion. 
To evaluate disease relapse detection, we determined the serum biomarker concen-
trations from three separate follow-up samples preceding the detection of relapse. 
The dynamics of the biomarkers during follow-up were evaluated and the number of 
patients with positive serum biomarker levels at each time point (exceeding the cut 
off) were calculated. 
4.4.3 Study III
The biomarker kinetics during treatment were evaluated separately for the PDS and 
NACT treatment arms for the CA125 and HE4 assays, respectively. A logarithmic 
transformation was run to correct for the skewness of the data. We evaluated the 
association of the baseline HE4 and CA125 concentrations to different end points 
(residual disease, tumor load) with t tests. The feasibility of the biomarker nadir 
values to predict platinum resistant progression were evaluated with Kaplan-Meier 
curves, and the statistical significance was explored with the log rank test and the sur-
vival curves were also assessed visually. The median nadir values, 14.0 U/ml and 57.2 
pmol/L, for the CA125 and HE4 assays were used as cut offs. The association of the 
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biomarker values at progression and survival (PFS, OS) were evaluated with Kaplan-
Meier curves and the Cox’s proportional hazards model. As OS has been suggested 
to be a suboptimal end point in cancer patients with a long survival post progression 
(SPP) (>6 months), we further evaluated the association of the biomarker levels at 
progression to SPP with Kaplan-Meier curves and the Cox’s proportional hazards 
model in an identical manner as described above. 
4.4.4 Study IV
Study IV was designed and carried out as a proof-of-concept study. Fishers exact test 
was run to detect significant changes in mutation frequency.
4.5 Ethical Aspects
All study participants signed a written consent at the time of enrolment.  The data 
was handled and analyzed according to the information security laws of the Euro-
pean Union.  The study was evaluated and accepted by the Ethics Committee in the 
Hospital District of Southwest Finland (I, II, III, IV) and the Regional Ethics Com-
mittee in South East Norway (I). 
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5 Results
The results presented here are reported in the original Studies I–IV. Additional, 
unpublished data on the potential of the conventional CA125, CA125-STn and 
-MGL assays to differentiate EOC from non-EOC malignancies are reported in 
chapter 5.1.1. The results of the longitudinal studies (II and III) are presented in the 
same chapters for the reader’s convenience, despite the slight differences in the study 
cohorts. In addition, unpublished, auxiliary results on the performance of the CA125 
glycoforms and HE4 are presented in Chapter 5.2.3. 
5.1 CA125 Glycoforms and EOC Diagnosis (I)
5.1.1 CA125 Glycoforms are EOC-specific Biomarkers
The median CA125, CA125-STn and -MGL concentrations were calculated for each 
histological subgroup of EOC, benign gynecological diseases, non-EOC malignan-
cies and healthy controls. All three biomarker assays presented significantly elevated 
serum concentration in serous, clear cell and endometroid carcinomas compared to 
benign gynecological diseases (Table 7). However, mucinous carcinoma was not ade-
quately detected by any of the assays (p=0.103, p=1.00 and p=0.157 for the CA125, 
CA125-STn and -MGL assays, respectively). 
The control cohort with healthy women was compared to those with benign 
gynecological diseases to evaluate the EOC-specificity of the glycoform assays.   The 
conventional CA125 assay presented significantly elevated serum concentrations in 
benign gynecological tumors (p=0.001), pelvic inflammation and adnexal torsion 
(p=0.047), and endometriosis (p<0.001) (Table 7). Altogether, the conventional 
CA125 assay presented falsely elevated serum levels in 36.6% (116/317) of patients 
with benign diseases (Table 8). Contrarily, significantly elevated CA125-STn concen-
trations were detected only in endometriosis (p<0.001), and not in benign tumors 
(p=0.14), pelvic inflammation or adnexal torsion (p=0.58). The CA125-MGL assay 
showed significantly elevated concentrations in benign tumors p=0.011) and endo-
metriosis (p<0.001). The CA125-STn and -MGL assays presented concentrations 
exceeding the cut offs in 17.0% and 27.8% of patients with benign gynecological 
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diseases, which is significantly less than with the conventional CA125 assay (p<0.0001 
and p=0.018, for the CA125-STn and -MGL assays, respectively) (Table 8).
Table 8. Women (N and %) with benign gynecological diseases or non-EOC malignancies and 
elevated CA125. Modified from Study I.
Histology CA125  
(>35.0 U/ml)
 CA125-MGL 
(>2.0 U/ml)
 CA125-STn 
(>10.0 U/ml)
 
 N % N % N %
Benign (all) 116 36.6 88 27.8 54 17.0
Neoplasms 50 39.7 35 27.8 12 9.5
Non-neoplastic 3 37.3 3 37.5 1 12.5
Endometriosis 63 34.4 50 27.3 41 22.4
Non-EOC 
malignancy*
16 84.2 16 84.2 5 26.3
*7 GI-carcinomas, 1 GIST, 1 biliary carcinoma, 1 SCC in MCT, 1 STUMP, 3 soft tissue 
sarcomas, 2 uterine endometroid carcinomas, 1 lymphoma, 2 unspecified non-EOC 
carcinomas
Interestingly, elevated serum CA125-STn levels were detected in particularly 
few non-EOC malignancies (5/19 patients, 26.3%) (Table 8). In contrast, conven-
tionally measured CA125 and CA125-MGL were elevated in nearly all patients with 
non-EOC malignancies (16/19 patients, 84.2% for both of the assays) (Table 8). We 
examined the discriminative potential (EOC vs. non-EOC malignancy) of the assays 
further with ROC curves, in which the CA125-STn performed with the highest AUC 
(0.852, CI: 0.785–0.919) (Figure 6). 
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Figure 6. ROC curves of the conventional CA125, CA125-STn and -MGL assays  
in discriminating EOC (N=232) from non-EOC malignancies (N=19).
5.1.2 The CA125 Glycoforms Improve the Detection of EOC 
Patients with marginally elevated concentrations of conventionally measured CA125 
generally present a diagnostic challenge for the attending gynecologist. We defined 
an arbitrary range of 35.0–300.0 U/ml for marginally elevated total CA125 levels 
to evaluate the applicability of the biomarkers in this subgroup comprehensively. 
Specific interest was directed at the postmenopausal population, as the number of 
premenopausal EOC patients in the current cohort was low.
Initially, the whole cohort (EOC N=232, benign N=317) was included in the 
ROC curve analysis, in which the combination of the CA125-STn and -MGL assays 
performed with the highest sensitivity at a fixed specificity of 90.0% (61.6%, p=0.014 
vs. 54.3% for the conventional CA125 assay). However, the AUC of the combined 
glycoform assays were similar to that of the conventional CA125 assay (p=0.107) 
(Table 9). Next, the postmenopausal subpopulation (EOC N=204, benign N=84) was 
analyzed and interestingly, the combination of the CA125-STn and -MGL exceeded 
the diagnostic ability of the conventional CA125 assay (p=0.021, AUC comparison, 
Table 9). This result was further reinforced in the marginally elevated subgroup (EOC 
N=63, benign N=35), in which the CA125-STn assay was superior in discriminating 
EOC from benign disease compared to the conventional CA125 assay (Figure 7). 
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Although both of the glycoform assays exceeded the diagnostic ability of the conven-
tional CA125 assay in this subgroup (p=0.042 and p=0.0023 for CA125-MGL and 
-STn, respectively), there was no additional diagnostic improvement to the AUC of 
the CA125-STn assay when the glycoform assays were combined (Table 9). 
Figure 7. ROC curves of the biomarkers in postmenopausal patients with marginally elevated 
CA125 (35.0–300.0 U/ml). N EOC: 63, N benign: 35. Modified from Study I.
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5.2 Longitudinal CA125-STn, -MGL and HE4 Analyses (II, III)
5.2.1 CA125 Glycoforms and HE4 During Primary HGSC Treatment 
The number of HGSC patients treated with PDS and NACT were proportionate in 
both of the study cohorts: 45.5% (PDS) and 54.5% (NACT), in Study II and 40.6% 
(PDS) and 59.4% (NACT) in Study III. The median biomarker concentrations in the 
PDS groups at baseline were 923.5 U/ml, 431.2 U/ml, 82.5 U/ml for the conventional 
CA125, CA125-STn and -MGL assays (II), and 918.0 U/ml and 750.5 pmol/L for the 
conventional CA125 and HE4 assays (III). The median baseline biomarker values 
in the NACT groups were 709.0 U/ml, 517.2 U/ml, 80.7 U/ml for the conventional 
CA125, CA125-STn and -MGL assays (II), and 838.7 U/ml and 773.4 pmol/L for the 
conventional CA125 and HE4 assays (III). Individual biomarker profiles of patients 
with different responses to treatment were visually evaluated and the kinetics of the 
biomarkers were found to be consistent (Figure 8). The biomarker concentrations 
declined most rapidly during the three initial cycles of chemotherapy regardless of 
the treatment regimen. At the conclusion of primary therapy, the median biomarker 
concentrations were lower in the PDS group; however, the dissimilarity was not 
found to be significant and consequently the treatment arms were combined for the 
prognostic analyses. 
Figure 8. Examples of individual biomarker profiles of patients during the primary  
treatment of HGSC. X-axis: time point during treatment, Y-axis: relative biomarker values 
(continues on the next page). 
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5.2.2 The CA125 glycoforms and HE4 are Indicators of Tumor Load 
The baseline serum biomarker values were compared to the tumor load assessed 
during surgery and the CA125-STn, -MGL and HE4 assays, contrarily to CA125, 
differentiated patients with a high tumor load (dissemination score 13–21) from 
patients with low tumor load (dissemination score 0–12) (p=0.030, p=0.026 and 
p<0.0001 respectively) (Table 10). A similar comparison was done on the association 
between baseline biomarker concentration and residual disease after cytoreductive 
surgery. Interestingly, a significant difference was detected in the baseline CA125-
STn and -MGL levels between patients with subsequent complete (R0) and subopti-
mal (R>0) cytoreduction (p=0.025 and p=0.022, respectively) (Table 10). Neither the 
conventional CA125 assay nor the HE4 assay distinguished between completely and 
deficiently debulked patients (p=0.154 and p=0.054), although HE4 was trending 
toward statistical significance (Table 10). No significant associations between the 
baseline biomarker levels and survival were observed.
Table 10. Comparison of baseline biomarker values (median, 25th and 75th quartiles) between 
subgroups A) Study II B) Study III. Modified from Study II and III. *P<0.05.
A CA125 (U/ml) CA125-MGL (U/ml) CA125-STn (U/ml)
Low tumor load 840.0 (440.0–2070.0) 69.4 (26.7–141.3) 243.9 (62.1–1048.6)
High tumor load 1024.5 (521.3–1846.8) 137.1 (51.6–211.3) 748.4 (258.6–1493.0)
P - value 0.363 0.026* 0.030*
R0 839.5 (362.0–1592.0) 54.6 (16.5–139.4) 219.7 (21.7–938.0)
R >0 918.0 (462.0–2323.8) 102.4 (33.8–206.9) 515.9 (170.8–1479.5)
P- value 0.154 0.022* 0.025*
B CA125 (U/ml) HE4 (pmol/L)
Low tumor load 652.0 (272.0–2105.0) 637.8 (346.1–891.0)
High tumor load 1038.0 (543.0–2342.5) 1043.6 (613.5–1189.0)
P - value 0.067 < 0.0001*
R 0 848.2 (274.3–2048.8) 716.8 (314.7–964.1)
R>0 916.0 (489.0–2272.0) 821.4 (476.5–1131.2)
P - value 0.641 0.054
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5.2.3 The CA125-STn and HE4 Nadirs Predict PFS 
In Study II, 54.9% of the patients developed disease recurrence during the median 
follow-up time of 21.5 months (range 2.3–118.6). The median time from the end of 
primary treatment to the detection of recurrence was 12.8 months (range 1.1–46.0). 
The median nadir values were 12.0 U/ml, 2.4 U/ml, 0.6 U/ml and 53.9 pmol/L for 
the conventional CA125, CA125-STn and -MGL, and HE4 assays, respectively. Optimal 
cut offs for the biomarker nadir values during primary treatment were independently 
determined for each assay with the Youden index method and they were as follows: 
33.0 U/ml CA125, 0.8 U/ml CA125-STn, 0.6 U/ml CA125-MGL and 54.3 pmol/L HE4. 
The analyses were run with the optimal cut off values determined for each assay. In the 
univariate analysis, the nadir value of CA125-STn >0.8 U/ml and the nadir value of 
HE4 >54.3 pmol/L were significantly associated with shorter PFS (p=0.02 and p<0.001, 
log rank test) while the nadir values of the conventional CA125 assay (p=0.154, log 
rank test) and the CA125-MGL assay (p=0.129, log rank test) were not associated with 
the PFS of patients. The CA125-STn nadir remained an independent prognostic factor 
in the multivariate analysis, contrarily to other clinical factors (residual disease, disease 
stage and age). Interestingly, when the nadir value of HE4 >54.3 pmol/L was added 
to the multivariate model, it emerged as the only statistically significant covariate 
(p=0.004; HR 2.36 and 95% CI 1.31–4.26) (Table 11). In this model, the CA125-STn 
nadir >0.8 U/ml had a HR of 2.28 (95% CI 0.87–5.98, p=0.095) (Table 11). The bio-
marker nadir values were not associated with the OS of patients.
Table 11. Associations of the biomarker nadir values and selected clinical variables to PFS with 
univariate (log rank test) and multivariate analyses (Cox regression model). The hazard ratio 
(HR) demonstrates the probability of a shorter PFS in patients with a specific clinical attribute. 
Modified from Study II. *P<0.05.
Clinical variable Univariate 
p-value
Multivariate 
p-value
Multivariate
HR
95% CI
Elderly (age>65) 0.20 0.55 1.17 0.70–1.95
Disease stage  
(FIGO 2014): III vs IV
0.38 0.45 1.23 0.72–2.11
R >0mm 0.80 0.46 1.27 0.67–2.41
CA125 nadir > 33.0 U/ml 0.15 0.60 1.21 0.60–2.41
MGL nadir >0.6 U/ml 0.13 0.88 1.05 0.56–1.95
STn nadir > 0.8 U/ml 0.02* 0.095 2.28 0.87–5.98
HE4 nadir > 54.3 pmol/L < 0.001* 0.004* 2.36 1.31–4.26
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5.2.4 CA125 and HE4 Nadir Values Predict Platinum Resistant Relapse
The applicability of the CA125 and HE4 assays to detect platinum resistant progression 
was evaluated in the Study III. The median nadir values were 14.0 U/ml (interquartile 
range 20.0) and 56.7 pmol/L (IQR 54.2) for the CA125 and HE4 assays. Compared 
to the CA125 assay, an earlier HE4 nadir was detected in 19 (26.8%) patients and 23 
(32.4%) patients had a later HE4 nadir. Platinum resistant relapse (PFI <6 months) 
was diagnosed in 26 (36.6%) patients during the follow-up period. Interestingly, 
the median CA125 and HE4 nadir values were different (p<0.0001, both assays) in 
the platinum resistant and platinum sensitive subgroups: 28.0 U/ml (IQR 41.0) and 
87.7 pmol/L (IQR 103.3) in the platinum resistant group, and 10.5 U/ml (IQR 11.3) 
and 49.7 pmol/L (IQR 27.07) in the platinum sensitive group. The association of 
the biomarkers to platinum resistant progression was further evaluated in a time-
to-event fashion with the Kaplan-Meier estimator curves. Nonetheless, patients with 
biomarker nadir values exceeding the median cut offs were at significantly higher 
risk of developing a platinum resistant progression (log rank test: CA125 p<0.0001 
and HE4 p=0.008).
5.2.5 CA125 Glycoforms and HE4 in Disease Relapse
The potential of the glycoforms to detect disease relapse was evaluated from serial 
serum samples leading to relapse. Interestingly, the CA125-STn levels increased 
earlier than the conventionally measured CA125 levels in 37.0% (13/35) of patients 
preceding the detection of relapse. At the detection of relapse, 80.0% (28/35) of the 
patients had higher fold increase in the serum CA125-STn concentrations compared 
to the conventional CA125 concentration. The CA125-MGL assay did not detect 
disease relapse earlier than the conventional CA125 assay; however, 11.0% (4/35) of 
patients had a higher fold increase measured with the CA125-MGL assay compared 
to the conventional CA125 assay. The CA125 glycoform assays detected relapse with 
similar performance as the conventional CA125 assay in 20.0% (7/35) of patients. 
Importantly, the glycoform assays detected disease relapse better or with similar 
performance as the conventional CA125 assay in all patients. Examples of individual 
progression profiles are presented in Figure 9. 
Longitudinal follow-up samples of HE4 were evaluable for 32 patients. A sup-
plementary analysis was done to assess where the HE4 alight on the detection of 
relapsed disease in comparison to the conventional CA125 and the glycoform 
assays. The HE4 assay showed earlier increase in 34.0% (11/32) of patients, while 
the CA125-STn levels increased earlier that the conventional CA125 assay in 31.0% 
(10/32) of patients. The HE4 and CA125-STn assays showed earlier increase in an 
equal number of patients (p=0.80). Preceding relapse, the CA125-MGL levels did 
not increase earlier than the conventionally measured CA125. A higher fold increase 
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was detected in 94.0% (30/32) of patients with the HE4 assay and in 81.0% (26/32) of 
patients with the CA125-STn assay (p=0.12). Three patients (9.0%) had a higher fold 
increase measured with the CA125-MGL assay compared to the conventional CA125 
assay. A similar performance to that of the conventional CA125 assay was detected 
in 3.0%, 15.0% and 91.0% of patients with the HE4, CA125-STn and -MGL assays, 
respectively.
Figure 9. Examples of CA125, CA125-STn and -MGL profiles leading to the detection of 
relapse (time point 4). Y-axis: the relative biomarker values. Modified from Study II.  
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5.2.6 HE4 and the Prognosis of Relapsed Disease
The average follow-up time of the patients was 2.5 years (range: 1.5 months to 10.2 
years) in Study III. The median survival post progression (SPP) was 16.0 months. 
At the time of progression, the median CA125 and HE4 concentrations were 162.0 
U/ml and 199.2 pmol/L, respectively. Two endpoints (overall survival and survival 
post progression) were used to comprehensively analyze the applicability of the bio-
markers in the prediction of the survival of the patients, as SPP has been suggested 
as a more appropriate endpoint in patients with a long (>6 months) survival after 
the detection of relapse (Broglio and Berry, 2009). In the univariate analysis, the 
serum HE4 concentration of >199.2 pmol/L was associated to both endpoints (OS: 
p<0.0001 and SPP: p=0.001) (Figure 10). In contrast, the CA125 concentration at 
relapse was not significantly associated to either of the endpoints (OS: p=0.13 and 
SPP: p=0.25) (Figure 10). Interestingly, less than 50.0% of the patients with a HE4 
concentration >199.2 pmol/L at progression were alive a year after the detection of 
progression, while half of the patients with serum HE4 <199.2 pmol/l at progression 
were alive two years after the detection of relapse (Figure 10). All patients with a SPP 
exceeding three years had a serum HE4 concentration <199.2 pmol/L at progression 
(Figure 10).
A subset of clinically relevant variables (disease stage, treatment strategy and 
residual disease) were selected for the multivariate model and each of them was at 
first evaluated univariately. Patients treated with NACT were found to have a worse 
OS (p=0.002, log rank test) in the above-mentioned analyses. However, the HE4 
concentration >199.2 pmol/L was the only variable independently associated with 
worse OS and SPP in the multivariate Cox regression model (OS: p=0.002 and SPP: 
p=0.001) (Table 12).
Table 12. The HE4 serum concentration of >199.2 pmol/L at progression  
was identified as an independent predictor of a worse overall survival  
(Cox regression model). Modified from Study III. *P<0.05.
Clinical variable Univariate p Multivariate p Multivariate HR (95% CI)
Disease stage:III vs IV 0.12 0.19 1.80 0.75–4.33
R > 0mm 0.51 0.43 0.71 0.30–1.67
PDS vs NACT 0.002* 0.07 2.20 0.94–5.15
CA125 >162.0 U/ml 0.13 0.60 1.25 0.53–1.67
HE4 >199.2 pmol/L < 0.0001* 0.002* 4.83 1.74–13.38
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Figure 10. The Kaplan-Meier curves of SPP of patients (N=40) with serum biomarker  
values below and exceeding the cut offs (medians) at progression. A serum HE4 concentration  
wof >199.2 pmol/L was significantly associated with the SPP (log rank test, p=0.001). A higher 
serum CA125 concentration at progression was not significantly associated with the SPP 
(p=0.252). Modified from Study III.
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5.3 Longitudinal Evaluation of ctDNA (IV)
5.3.1 CtDNA and the Tumor Mutation Profile
The OseqTM ctDNA solid tumor panel with subsequent variant and CNA calling 
were applied in the analyses. The OseqTM ctDNA panel is designed for solid tumors 
including lung cancer, colorectal cancer, ovarian cancer, breast cancer, melanoma 
and lymphoma. After calling and filtering, 265 mutations in 185 genes and CNA 
aberrations in 113 genes were approved for further evaluation. The applicability of 
plasma ctDNA as a snapshot of the tumor tissue mutation environment was evaluated 
by comparing plasma mutations to tumor biopsies obtained during surgery. Overall, 
the plasma ctDNA mutation profiles were similar to the mutations detected in tumor 
tissue (79% median concordance in mutations and 74% in CNAs) (Table 13). The 
decisive filtering progress and the exclusion of alterations derived from blood cells 
(germline sample analysis) maximized the likelihood of the detected mutations to be 
derived from the actual tumor and not confounding factors, i.e. clonal hematopoiesis.
Table 13. The individual mutation concordances between plasma and tissue.  
The median concordance was high (79%). Modified from Study III.
Tissue(s) PFI 
group
Plasma 
only (N)
Both 
(N)
Both 
(%)
Tissue 
only (N)
Total
EOC587 Baseline adnexa; IDS liver poor 16 19 54% 0 35
EOC677 Baseline peritoneum;  
IDS ovary; prog ascites
poor 3 33 92% 0 36
EOC736 Baseline adnexa;  
IDS ovary
poor 0 22 100% 0 22
EOC183 Baseline and  
IDS omentum
poor 4 25 86% 0 29
EOC568 Baseline adnexa;  
IDS ovary
poor 2 11 85% 0 13
EOC1067 PDS omentum;  
prog ascites
poor 11 19 61% 1 31
EOC1030 PDS ovary good 7 14 54% 5 26
EOC49 Baseline and  
IDS omentum
good 9 36 80% 0 45
EOC415 PDS omentum good 1 8 80% 1 10
EOC1099 PDS ovary good 0 5 56% 4 9
EOC429 PDS omentum good 0 10 77% 3 13
EOC998 PDS ovary good 6 4 40% 0 10
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The frequency of the TP53 mutation was assessed and, not surprisingly, it was 
detected in all 12 patients. A moderate positive correlation between serum CA125 and 
the plasma TP53VAF was discovered (median 0.67, range 0.16–0.97). In addition, the 
CNAs detected with PanelDoc were strongly correlated (0.88) with the ctDNA por-
tion of the cfDNA. In consideration of these results, ctDNA seem a feasible indicator 
of the tumor mutation environment in HGSC.
5.3.2 CtDNA and Treatment Monitoring 
In 75.0% (9/12) of the patients, the ctDNA profile matched the clinical treatment 
outcome. One patient was excluded from the current analysis, as the baseline plasma 
sample had a too low tumor content for the accurate estimation of significant 
changes. The longitudinal changes in the ctDNA mutation profiles were different 
between patients with a good and a poor response to treatment: good responders 
were found to have significantly lower amounts of mutations and a higher proportion 
of mutations with decreasing VAF during primary therapy (p=0.008). Importantly, 
these differences were already detected early on in the treatment schedule (before the 
2nd and 3rd cycles of chemotherapy) (Figure 11). 
Figure 11. Patients with ctDNA profiles matching the clinical outcome. The reduction of the 
tumor content (%) in plasma happened during the first cycles of chemotherapy in patients with 
a good response to treatment, while poor responders showed persistently elevated levels of 
tumor content during therapy (p=0.008). Modified from Study III.
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Next, specific attention was directed at poor responders and the genes with 
stable or increasing mutation VAFs during treatment. Enriched pathways detected 
in the poor responders included transcription, p53, chromatin regulatory and DNA 
double-strand break repair pathways. The chromatin regulatory pathways were the 
most selectively enriched and included 10 genes, of which some have been associated 
with DNA replication fork degradation and the development of therapy resistance 
(KMT2A, KMT2B, KMT2D, KDM5A, and SUZ12). 
5.3.3 CtDNA Reveals Actionable Mutations 
The motivation for the ctDNA analyses were to obtain a non-invasive snapshot of 
the actionable mutations in the patients’ malignancies. Potential, clinically actionable 
mutations were detected in the plasma ctDNA of seven patients (Table 13). The muta-
tions were positioned in four engaging complexes: mammalian target of rapamycin 
(mTOR; patients EOC429, EOC49), DNA repair (patients EOC429, EOC677, and 
EOC1067), epidermal growth factor receptor (EGFR; patients EOC587, EOC736, 
and EOC568), and cyclin dependent kinases (CDKs; patient EOC1067). 
Mutation mediated over activation of the mTOR-pathway was detected in the 
plasma ctDNA of patients EOC429 (mutation in the NF1 gene) and EOC49 (muta-
tion in the PTEN gene). Recent studies indicate that ovarian cancer patients with 
mTOR-pathway amplification might be responsive to phosphatidylinositol 3-kinase/
mTOR inhibitors (Mabuchi et al., 2015). Furthermore, carboplatin has been described 
to effectively influence the apoptosis of cancer cells through the mTOR pathway 
(Zhou et al., 2018). In the current study, both patients with mTOR overactivation 
responded well to platinum-based chemotherapy (Table 14). Additionally, EOC429 
had a deleterious mutation in the RAD51C gene resulting in HR deficiency, which 
makes the disease susceptible for platinum-based chemotherapy (Table 14). 
Three patients (EOC429, EOC677 and EOC1067) were found to have mutations 
and CNAs in genes associated with DNA repair. We detected mutations both in 
BRCA2 and STAG2 in the ctDNA of patient EOC677; however, the frequency of the 
mutations was low being suggestive of subclonal events. One patient (EOC1067) had 
a somatic deletion of FANCA with concurrent deletions in CDKN1B and CDKN2B, 
and although these mutations convey HR-deficiency and PARPi-sensitivity, disease 
progression was already detected at 8.9 months after the conclusion of the plati-
num-based chemotherapy (Table 14).
Three patients had mutations or CNAs in the EGFR pathway, which gener-
ally make tumors susceptible for EGFR inhibitors (i.e. trastuzumab, a humanized 
monoclonal anti-ERBB2 antibody). Patient EOC736 had been treated with NACT, 
subsequent IDS and adjuvant chemotherapy consisting of paclitaxel and carboplatin. 
Although a complete response to the primary therapy was achieved, the TP53VAF 
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remained elevated throughout the treatment in the ctDNA analyses. Based on the 
current study, persistently elevated TP53VAF indicates a suboptimal response to 
treatments and in patient EOC736 it had already progressed 5 months after the con-
clusion of primary therapy. Pegylated liposomal doxorubicin (PLD) was selected as 
the second line treatment. Despite the PLD the patient’s condition worsened and the 
serum CA125 concentration rose (Figure 12). At progression, the patient’s ctDNA 
analysis revealed a high copy-count amplification of the ERBB2 gene. A decision to 
include trastuzumab in her treatment was done based on the current ctDNA analy-
sis result. Intriguingly, the patient achieved a complete serological response (serum 
CA125 reduced from 840.0 U/ml to 19.0 U/ml) after the change in chemotherapy 
from PLD to a combination of trastuzumab, carboplatin and paclitaxel (Figure 12). 
A CT scan showed a significantly reduced tumor load and a partial response to treat-
ment was concluded in accordance with the RECIST criteria (Eisenhauer et al., 2009).
Figure 12. At progression, a high copy-count amplification of the ERBB2 gene was detected 
in the ctDNA of patient EOC736. Despite treatment with PLD the patient’s condition worsened 
and serum CA125 concentrations began to rise. Based on the ctDNA analysis, trastuzumab 
was added to the treatment regimen and a partial response was achieved (RECIST criteria). 
Modified from Study IV.
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6 Discussion
Epithelial ovarian cancer is characterized by an unfavorable outcome and it is, 
alongside cervical cancer, the most lethal gynecological malignancy in the developed 
countries (Bray et al., 2018). Early diagnosis has proven to be very difficult, mostly 
due to the lack of specific symptoms and accurate biomarkers. Although aggres-
sive surgical effort and the implementation of platinum-based chemotherapy have 
improved the survival of patients, eventually, the vast majority of patients develop a 
treatment resistant, progressive disease.   
CA125 is currently the only biomarker validated and widely used in the diagno-
sis, treatment monitoring and follow-up of EOC. However, CA125 is not the ideal 
biomarker as 1) it does not detect early stage EOC with the accuracy needed, 2) it 
does not precisely portray tumor load and 3) it is unspecific for EOC. Consequently, 
biomarker research has been a hot topic and it has generated potential, new tumor 
marker candidates. One of them is HE4, which was recently approved as an auxil-
iary biomarker for CA125 in the diagnosis of EOC. Unfortunately, HE4 has since 
been found to be elevated in several other malignancies and non-cancerous diseases, 
which limits its utility as a diagnostic marker in EOC. All things considered, there is 
still a dire need for better EOC biomarkers. 
6.1 CA125 Glycoforms and EOC Diagnosis
Based on this study, the CA125-STn and -MGL assays detected the most common 
EOC subtype, HGSC, adequately (p<0.001, both assays) and showed good diag-
nostic applicability particularly in postmenopausal patients. A further diagnostic 
advantage was achieved when the conventionally measured CA125 was marginally 
elevated (35.0–300.0 U/ml). In the current cohort, the diagnostic performance of the 
conventional CA125 assay was slightly inferior to that reported in previous studies 
(AUC 0.78 vs 0.87)  (Wang et al., 2014). Not surprisingly, neither the conventional 
CA125 assay or the glycoform assays detected the mucinous histotype of EOC, 
and additional biomarkers might need to be combined for the diagnostic coverage 
of mucinous carcinoma. Endometroid, low grade serous and clear cell carcinomas 
were sufficiently detected by all of the biomarker assays. Importantly, the number 
of patients with a benign disease and elevated CA125 concentrations was markedly 
72
Liina Salminen
reduced with the application of the glycoform assays. The leading concern regarding 
the low specificity of the conventional CA125 assay is the subsequent additional test-
ing and emotional anguish after a falsely elevated test. Based on the current results, 
the glycoform assays might be feasible tools in decreasing these unnecessary, often 
invasive, diagnostic procedures. 
The measurement of glycoforms to increase the diagnostic specificity of conven-
tional biomarkers have also been explored in other cancers (Korekane et al., 2012; 
Kirwan et al., 2015). Indeed, the LCA-reactive fraction of alpha-fetoprotein (AFP-L3) 
has been validated as a more specific biomarker than total-AFP and is currently used 
in the clinical setting in the diagnosis of hepatocellular carcinoma. Little is known 
about the function of altered glycosylation seen in cancers regardless of the tumor 
type. It has been hypothesized that altered glycosylation might be part of a larger 
“metastatic code” of cancers contributing to disease progression and metastasis 
(Fuster and Esko, 2005). Consequently, it is likely that glycoforms show better prog-
nostic performance than their conventional counterparts.
There are several multimarker panels designed for the differential diagnosis 
of pelvic masses. Currently, the Risk of Ovarian Malignancy Algorithm (ROMA), 
Risk of Malignancy Index (RMI) and the Copenhagen Index (CPH-I) are the most 
widely used in clinical settings (Van Gorp et al., 2011; Anton et al., 2012; Moore et 
al., 2013). These panels build on the tumor markers CA125 and HE4, TVS and the 
patients menopausal status/age. However, TVS is an operator-dependent modality 
and the accuracy of the panels vary. The sensitivity and specificity of the multimarker 
panels have been reported to be 67% to 94% and 75% to 92% between studies. Based 
on the current study, the CA125 glycoform assays could bring additive value to the 
contemporary diagnostic metrics both as individual markers and as putative parts 
of multimarker panels. The CA125 glycoform assays, similar to CA125 and HE4, 
present an objective result utilizing a robust technique. A commercialized version 
of the CA125-STn and -MGL assays would in no way differ from conventional, fully 
automized sandwich assays.
6.2 CA125 Glycoforms and HE4 in the Preoperative  
Evaluation and Prognostic Stratification of HGSC
The cohorts used in the longitudinal CA125-STn, -MGL and HE4 analyses differed 
slightly in the number of patients; however, all patients were diagnosed with HGSC, 
the biomarker measurement and follow-up schedules were identical and, due to this, 
the results of these two studies (II and IV) are discussed simultaneously below and 
in the Chapter 6.3.
In the current study, the longitudinal kinetics of the CA125-STn and -MGL assays 
were found to be consistent during primary HGSC treatment and comparable to that 
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of the conventional CA125 assay. Moreover, the dynamics of HE4 during HGSC 
treatment was consistent, and we did not detect discrepancies between the HE4 and 
CA125 dynamics in the current cohort contrary to the study by Ferraro et al (Ferraro 
et al., 2018). However, the cohort analyzed by Ferraro et al. was heterogeneous and it 
also included non-epithelial ovarian malignancies. Consequently, these two studies 
are not absolutely comparable. 
The main result in the longitudinal biomarker analyses were the association of the 
baseline CA125-STn, -MGL and HE4 with the tumor load assessed during surgery. 
Unsurprisingly, the conventional CA125 assay showed no such association, which 
is in line with the evidence of discrepant CA125 concentrations with actual disease 
extent (Bast et al., 2005). No optimal cut off values in separating high tumor load 
patients from those with a low tumor load for the CA125-STn, -MGL or HE4 assays 
were determined, and the exploration of this subject remains for further studies. 
Currently, the modalities for the preoperative evaluation of tumor load are contrast 
enhanced (ce)CT and in selected patients and hospitals positron emission tomogra-
phy (PET)/CT. In addition, diagnostic laparoscopy is done in many tertiary referral 
hospitals to achieve the most accurate assessment of operability. The accuracies of 
these modalities for the assessment of tumor load have been reported to be 57% and 
85% for ceCT between studies, 64% and 91% for PET/CT between studies and 90% 
for diagnostic laparoscopy (Fagotti et al., 2005; Kitajima et al., 2008; Hynninen et al., 
2013). Instinctively, the measurement of serum biomarkers would act as a comple-
mentary, non-invasive method in the evaluation of operability.
The results of this study indicate that both the CA125-STn and -MGL assays 
might be better predictors of residual disease than the conventional CA125 and HE4 
assays. Our results are in line with previous studies on the utility of the conventional 
CA125 assay in the prediction of the amount of residual disease (Barlow et al., 2006; 
Kang et al., 2010; Mury et al., 2011). In the current cohort, baseline HE4 was not 
significantly associated with the amount of residual disease, although there was 
a tendency of higher serum HE4 concentrations in patients with macroscopic resid-
ual disease. In consequence, our study does not offer further support to the previous 
studies on HE4 and residual disease (Angioli et al., 2013; Braicu et al., 2013; Vallius 
et al., 2017).  Parallels can be drawn between the amount of residual disease after 
cytoreductive surgery and the initial tumor load of the patient; however, these two 
variables do not entirely characterize the same feature as already small amounts 
of tumor on unresectable anatomic locations might lead to significant quantities of 
residual disease. Again, no specific cut offs for the biomarkers in the prediction of 
residual disease were determined in the current study. The HE4 cut offs suggested 
by Angioli et al and Braicu et al were 267.0 pmol/L and 235.0 pmol/L, respectively, 
and considering the median HE4 concentration at baseline in the current cohort 
(806.4 pmol/L) the cut offs appear utterly strict in the two above-mentioned studies 
(Angioli et al., 2013; Braicu et al., 2013). 
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In clinical trials, an assessment tool for the timely evaluation of tumor load and 
the prognostic stratification of patients during primary treatment is needed. Here, the 
nadir CA125-STn level of >0.8 U/ml was identified as an independent predictor of PFS, 
while the CA125-MGL and the conventional CA125 assays showed no such association. 
In the complementary analyses, the HE4 nadir >54.3 pmol/L was also identified as a 
predictor of PFS and showed stronger correlation to PFS than the CA125-STn assay in 
the multivariate analysis. In Study II, optimal cut offs for each assay were determined 
independently and PFS was dichotomized into progression vs no progression, which 
differs from the analysis in Study III, in which the nadir values were evaluated in the 
prediction of platinum resistant relapse. In the light of these results, the CA125-STn 
and HE4 assays seem to identify patients who develop progression more rapidly, even 
after the 6-month pillar of platinum resistant relapse. In the current cohort, both 
the conventional CA125 and the HE4 assays were adequate tools in the detection of 
patients with particularly poor outcomes (PFI <6 months). Our results on the CA125 
and HE4 nadir values are in line with previous studies on the subject (Kang, Seo and 
Park, 2009; Van Altena et al., 2010; Xu et al., 2013; Vallius et al., 2017).
6.3 CA125 Glycoforms and HE4 in Recurrent HGSC 
Despite a satisfactory response to primary treatment, most of the patients with HGSC 
eventually develop recurrent disease. In the literature, the serum concentration of 
conventionally measured CA125 has been reported to rise approximately 3 months 
before a subsequent symptomatic recurrence (Bast et al., 2005). However, the results 
of two large, multicenter trials are contradictory on the concordance of conventionally 
measured CA125 to radiologic response criteria (Alexandre et al., 2012; Lindemann 
et al., 2016). In the current study, the CA125-STn showed elevated serum CA125 
concentrations prior to that of the conventional assay in 37.0% (13/35) of patients 
and higher in fold increase in 80.0% (28/35) of patients. The CA125-MGL assay did 
not detect recurrence earlier than the conventional CA125 assay, but a higher in fold 
increase was detected in 11,0% (4/35) of the patients. The results indicate that spe-
cifically the CA125-STn assay might be able to detect very small amounts of tumor 
growth and could consequently show better concordance to radiologic response eval-
uation criteria than the conventional CA125 assay. In the complementary analyses, 
the HE4 assay performed equally well as the CA125-STn assay in the detection of 
relapse. This finding is in line with previous results, which have suggested a lead time 
of 5–8 months to the conventional CA125 assay with the HE4 assay (Anastasi et al., 
2010).
Without doubt, the conclusion of the study by Rustin et al, questioning the bene-
fit of routine measurement of conventional CA125 in asymptomatic women after the 
conclusion of primary therapy (Rustin et al., 2010), raises the question of whether our 
75
Discussion
result on the earlier detection of asymptomatic recurrence is of clinical value. Firstly, 
with the development and implementation of new targeted therapies, i.e. PARPi and 
immunological drugs, the advantage of early treatment of asymptomatic recurrence 
needs to be re-evaluated, and secondly, well-designed trials with biomarkers already 
detecting recurrence in small tumor volumes are needed when investigating the clin-
ical applicability of these new therapies. 
Based on the current study, the serum HE4 concentration at the time of relapse 
is associated with the survival of patients and in consideration of this, HE4 might 
well be an indicator of disease aggressiveness.  In contrast, conventionally measured 
CA125 did not show such an association. Overall, HE4 is a promising auxiliary tool 
to the conventional CA125 assay in the detection of recurrent disease and it could 
aid clinicians in choosing the most appropriate second line treatment in this era of 
targeted therapies.
6.4 Identification of Actionable Mutations in ctDNA
The mechanisms behind acquired treatment resistance are heterogeneous and still 
unapprehended to a large extent. The results of the current study showed that the 
tracking of relevant ctDNA mutations during the treatment and follow-up of HGSC 
is a feasible method in the timely detection of treatment resistance. The ctDNA anal-
ysis predicted the treatment response of the patients: poor responders were found 
to have a higher mutation burden and less mutations with a decreasing VAF during 
treatment. These findings are in good concordance with the premise that a stable or 
increasing abundance of mutations result from underlying selection processes asso-
ciated with specific treatments and the development of treatment resistance (Murtaza 
et al., 2013). Interestingly, in the current study, these differences were already seen in 
the early phases of the treatment regimen, i.e. after cytoreductive surgery and after 
the 2nd cycle of chemotherapy. 
Importantly, the ctDNA mutations profiles were found to be comparable to the 
aberrations in the tumor tissue biopsies taken during surgery, which is a prerequi-
site for the utilization of ctDNA altogether. The germline and ctDNA comparison 
increased the likelihood of the mutations originating from the tumor further. Indeed, 
as indicated by previous studies (Asante et al., 2020), ctDNA appeared to be a feasible 
method in the real-time assessment of intratumor diversity and clonal evolution. 
CtDNA analysis might be especially advantageous in situations where conventional 
biopsies are unattainable or if there is reason to believe that conventional biopsies 
would not represent the tumor in an up-to-date manner, i.e. heavily pretreated 
patients, fast-growing and/or necrotic tumors.
Actionable mutations with possible clinical applicability were detected in the 
ctDNA of seven HGSC patients (58.0%). One patient with a platinum resistant 
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progression and a poor response to conventional therapy (pegylated liposomal 
doxorubicin) was detected to have a high-confidence ERBB2 amplification in the 
ctDNA analysis. ERBB2, a transmembrane receptor tyrosine kinase, is a member of 
the epidermal growth factor receptor (EGFR) family (Chung et al., 2019).  ERBB2 
transduces proliferative and survival signals to the cell as a homodimer (without 
ligand stimulation) or a heterodimer with other EGFR family members upon ligand 
stimulation (Ménard et al., 2000). Based on the ctDNA results, the treatment of the 
patient was changed to a combination of trastuzumab, reduced dose carboplatin and 
paclitaxel, and compellingly, a complete normalization of CA125 was seen after two 
months of the change in therapy. A previous study reported similar results, in which 
three patients out of seven (42.8%) with ERBB2 amplifications reached a complete 
response to treatment after the implementation of trastuzumab (Ray-Coquard et al., 
2008). These results indicate that trastuzumab might reverse the therapy resistance 
of patients with ERBB2 amplification. However, little is known about the exact role 
of the ERBB2 amplification in the development of therapy resistance, and in vitro 
analyses have suggested that, instead, the molecules involved in its signaling path-
way might be the true protagonists in the development of ERBB2 induced therapy 
resistance (Ménard et al., 2000). Indeed, the precise mechanism of the anti-tumor 
activity of trastuzumab is also not completely understood and proposed mechanisms 
include the inhibition of the ERBB2-mediated pathway and antibody-dependent 
cell-mediated cytotoxity (Minami et al., 2013). Although ERBB2 amplification is rare 
in ovarian cancer (5.7%, in situ hybridization) (Chung et al., 2019), it might be an 
indicator of poor prognosis and an object for targeted therapies and consequently, 
ERBB2 testing of selected, relapsed HGSC patients deserves consideration. 
6.5 Strengths and Limitations
All serological sample analyses were done by a blinded investigator in an identical 
manner, which is a strength of the study. However, two different kits for the meas-
urement of the conventional CA125 serum concentrations were used and this can be 
seen as a limitation of the study, despite the good correlation between the two kits. 
Another limitation of the study is that some of the serum samples were stored for a 
long time, the oldest samples for 10 years, and the quality of the samples were not 
controlled at the initiation of the study. Both CA125 and HE4 have been reported to 
be stable molecules and no degradation was detected after 5 years of storage at -80 
°C in a study on the effect of long term storage on CA125 and HE4 concentrations 
(Sandhu et al., 2014).  
 The goal when assembling the cohort for Study I was to cover a clinically rel-
evant, heterogeneous subset of patients. Consequently, the diagnostic performance 
of the assays should be well translatable to real clinical circumstances. However, 
77
Discussion
the number of patients with rarer histological subtypes of EOC were few, and it is dif-
ficult to draw conclusions on the diagnostic potential of the CA125-STn and -MGL 
assays in these groups as the statistical power is low.
The strengths of the longitudinal studies are the prospective study setting, stand-
ardized treatment regimens and response evaluation criteria. A limitation of the 
studies is the lack of serum samples at one or several individual timepoints in the 
sample series of some patients. However, the longitudinal kinetics of the biomarkers 
were consistent throughout the primary treatment and follow-up of the patients. The 
tumor load was exclusively assessed by the operating gynecologic oncologist and it 
was not confirmed from imaging studies. A further limitation is that the interob-
server variability was not evaluated and, in this context, an observer bias is possible.
We included over 500 cancer-related genes in the ctDNA analysis, which enabled 
a comprehensive analysis of somatic mutations and CNAs. The obvious limitation of 
the ctDNA study is the low number of patients. However, the study was designed as a 
proof-of-concept study and this limitation was evident already at the planning phase 
of the study. 
6.6 Future Perspectives
The diagnostic performance of the CA125-STn and -MGL assays need further assess-
ment and the preferred next step in the validation process is a multicenter trial with 
an increased heterogeneity in the study population. The current exploratory studies 
have provided a good foundation for further validation. Moreover, the technical 
development of the assays is still ongoing, with the goal to reduce the number of 
false positive cases further. A very high specificity is needed for a biomarker to be 
potentially applicable as a screening tool, and future studies will show whether the 
glycoform assays are suitable for the task. 
The routine measurement of HE4 during treatment and follow-up is currently 
not included in the treatment recommendations of HGSC (Colombo et al., 2019). 
However, in the current study the prognostic potential of HE4 at disease progression 
was observed. Further studies on the subject are warranted in addition to studies 
evaluating the feasibility of treating asymptomatic, early progression with new, tar-
geted therapies 
The longitudinal tracking of ctDNA mutation profiles show promise in finding 
therapeutic windows during the primary therapy and follow-up of HGSC. Little is 
still known about the genetic alterations behind the development of treatment resist-
ance and future studies on ctDNA might shed additional light on the matter.
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7 Conclusions
The following conclusions can be drawn based on this work:
1. The CA125 glycoforms, CA125-STn and -MGL, are potential new bio-
markers of EOC. Both of the assays showed better EOC-specificity than 
the conventional CA125 assay.
2. The longitudinal kinetics of the CA125-STn, -MGL and HE4 assays 
showed good concordance with the conventional CA125 assay and the 
treatment response of the patients.
3. The baseline concentrations of the CA125-STn, -MGL and HE4 assays 
were significantly associated with the tumor burden assessed during 
surgery and these biomarkers might serve as auxiliary tools in the eval-
uation of up front cytoreductibility.
4. The landscape of EOC treatment is rapidly changing due to the develop-
ment and implementation of new targeted therapies. The new therapies 
are specifically changing the notion of recurrent disease and patients 
live longer with stable diseases. The CA125-STn and HE4 assays are 
sensitive indicators of recurrence and might be potential tools in the 
selection of second line treatments. Studies on the feasibility of treating 
asymptomatic, serological recurrence are warranted.
5. A strongly elevated serum HE4 concentration at progression might be 
associated with a more aggressive relapse, which could ease the prog-
nostic stratification of patients.
6. A longitudinal ctDNA analysis with a large panel reveals actionable 
mutations and opens potential therapeutical windows both during the 
primary therapy and follow-up of patients with HGSC.  
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